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Aim and outline of the study 

AIM AND OUTLINE OF THE STUDY 
The work described in this thesis was promoted by the clinical presentation of 
a patient with a first attack of rhabdomyolysis. This patient was admitted to 
the neurological department in a confused state and suffered from muscle 
weakness and moderate renal failure. The diagnosis rhabdomyolysis was 
established and after being adequately treated, the patient made a complete 
recovery. As all common traumatic, mechanical, infectious and toxic causes of 
rhabdomyolysis had been excluded, a metabolic etiology seemed most likely. 
However, in spite of careful biochemical assesment for the etiology, initially 
no classifying diagnosis could be established to explain the attack of rhab­
domyolysis. Since we were able to follow this patient for a couple of years, fur­
ther metabolic study was performed. In the same period more patients pre­
sented with unexplained attacks of rhabdomyolysis. The diagnostic problems 
promoted further research for etiologies of muscle cell necrosis. Subsequently 
the question was put forward how to prevent the development of recurrent 
rhabdomyolysis. 
The aims of the study, concerning these two aspects, were: 
I. To recognize new etiologies of muscle necrosis, additional to the known 
hereditary and acquired causes, in patients with unexplained rhabdomyo­
lysis. 
п. To investigate the role of calcium homeostasis in relation to muscle cell 
necrosis and the therapeutic value of dantrolene sodium in the prevention 
of recurrent rhabdomyolysis. 
In CHAPTER 2 the subject is introduced by a review of literature with respect 
to the clinical and biochemical features of rhabdomyolysis, the complications, 
the etiology and the therapeutic measures. 
The study can be divided into two parts. Section ι (CHAPTER 3.1-3.4) deals 
with the investigations in patients with unexplained rhabdomyolysis. Clinical 
examination, physiological study and biochemical assessment is performed to 
search for new and yet unknown acquired or hereditary causes of rhabdomyo­
lysis. Section π (CHAPTER 4.1-4.4) concerns the role of calcium homeostasis in 
relation to rhabdomyolysis and the prevention of muscle necrosis by dantro­
lene sodium. For this purpose a comparison is made to the syndrome of 
malignant hyperthermia (мн), the most life-threatening form of rhabdomyo­
lysis. It is generally accepted that malignant hyperthermia is a disorder con­
fined to skeletal muscle, in which the myoplasmic calcium concentration is 
abnormally regulated.1 The only established reliable diagnostic test for мн 
susceptibility involves the in vitro contraction test (г ст) of biopsied skeletal 
muscle.2 Since a breakdown in the mechanism regulating the calcium influx 
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into cytoplasm, like in мн, is presumed also to underly rhabdomyolysis, six 
patients with unexplained rhabdomyolysis are investigated with the in vitro 
contraction test (IVCT). Calcium homeostasis is studied in cultured muscle 
cells in one of these patients. The results of these studies (CHAPTER 4.1) under­
line the role of a dysregulation in calcium homeostasis in the process of rhab­
domyolysis. 
The only therapy of choice in malignant hyperthermia is intravenous admin­
istration of dantrolene sodium. Dantrolene sodium is a direct acting muscle 
relaxant which impairs muscle contraction by decreasing the release of cal­
cium ions from sarcoplasmic reticulum.3 It diminishes the influx of calcium 
ions into cytosol and depresses the trigger mechanism for the excitation-con­
traction coupling. 
Analogous to the use of dantrolene sodium in the treatment of malignant 
hyperthermia, two experimental studies are performed to test the effect of 
dantrolene sodium in the prevention of recurrent rhabdomyolysis. 
An animal model is used (CHAPTER 4.2) to study the electrophysiological 
results of the influence of dantrolene sodium on the development of electric­
ally silent muscle contractures in male whistar rats with an induced glycolytic 
enzyme block. 
Subsequently a group of patients with McArdle's disease, a well-defined disor­
der of glycogenosis with frequently occurring rhabdomyolysis,4 is investi­
gated, CHAPTER 4.3 deals with the muscular problems of these McArdle 
patients and the influence of dantrolene sodium on their exercise-tolerance. 
Electrophysiological studies are performed to study the effect of dantrolene 
sodium during the first 15 minutes of exercise (the adaptation phase). Both 
subjective effects of pharmacological intervention and objective electrophys­
iological changes are recorded. 
Finally the treatment of dantrolene sodium in two individual patients with 
recurrent exertional rhabdomyolysis is evaluated in CHAPTERS 3.4 and 4.4. 
In CHAPTER 5 the results of the study are summarized and discussed, followed 
by the major guidelines for the clinician how to handle the problem of rhab­
domyolysis. 
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CHAPTER 2 
Rhabdomyolysis: a review of literature 
P.J.E. Poels and F.J.M. Gabreëls 
Clinical Neurology and Neurosurgery (in press) 
Summary 
Rhabdomyolysis (lysis of skeletal muscle cells) is a potentially lethal syndrome 
with a broad spectrum of clinical and biochemical findings. Myalgia, pigment-
uria and elevated activity of serum creatine kinase are the common features. 
Fulminant rhabdomyolysis may be associated with severe metabolic distur-
bances and involvement of other organ systems. Cardiac arrest, compartment 
syndrome and acute renal failure are the major complications. The extent of 
the life-threatening complications of rhabdomyolysis strongly depends on 
early diagnosis and adequate therapy. As the repair mechanism of striated 
muscle functions very well, the prognosis of adequately treated rhabdomyo-
lysis is excellent. This article reviews the present state of knowledge about 
clinical and biochemical diagnosis of rhabdomyolysis, the pathophysiologic 
background, the classification and the etiological provocative factors. 
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Introduction 
Rhabdomyolysis denotes an acute or subacute event which leads to necrosis of 
striated muscles. The clinical features may vary widely from moderate muscu-
lar symptoms to life-threatening complications. Rhabdomyolysis has fre-
quently been associated with the seamier aspects of life and society: alcohol 
abuse, drug addiction, sadistic drill exercises, battering of children, war 
events, and attempted suicide. 
The earliest description of rhabdomyolysis is found in the Book of Numbers 
of the Holy Bible.1 The many deaths among the Jews during their exodus 
from Egypt are ascribed to their abundant consumption of quail. In 1881 the 
syndrome of myoglobinuria is considered in the German literature as a new 
form of hemoglobinuria.2 In the twentieth century the idiopathic form of 
rhabdomyolysis has been described extensively by Meyer-Betz.3 During the 
second world war Bywaters and Beali gave account of the major clinical 
sequelae of traumatic rhabdomyolysis, including acute renal failure as one of 
the main complications.4 In recent years numerous case reports have been 
published about rhabdomyolysis and its divers causes in many medical spe-
cialties and a growing number of metabolic defects have been identified.5,6 
Neurologists deal with the clinical problems of rhabdomyolysis in two differ-
ent ways. On the one hand, patients with severe rhabdomyolysis may be 
comatose and subsequently develop significant metabolic disturbances 
involving the central and peripheral nervous system. On the other hand, 
patients with mild or recurrent rhabdomyolysis may present with exercise-
related neuromuscular signs and symptoms requiring further search for an 
underlying metabolic defect. 
In this review we present the spectrum of clinical and biochemical findings in 
patients with severe and mild forms of rhabdomyolysis as reported in the lit-
erature from the past decades in order to provide diagnostic and therapeutic 
guidelines for the clinician. 
Definition 
Rhabdomyolysis is defined as a clinical and biochemical syndrome resulting 
from skeletal muscle injury that alters the integrity of the muscle cell mem-
brane sufficiently to allow the release of the muscle cell contents into the plas-
ma. Rhabdomyolysis may cause visible pigmenturia as a result of the presence 
of myoglobin in urine. 
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Myoglobinuria is generally used as a synonyme for rhabdomyolysis. Bowden 
et al. suggested the term rhabdomyolysis to highlight the fact that the funda­
mental problem in myoglobinuria concerns the muscle and is not primarily 
related to either myoglobin or renal failure.7 In fact, myoglobinuria does not 
exist without rhabdomyolysis, but rhabdomyolysis does not necessarily result 
into visible myoglobinuria. Moreover, many constituents other than myoglo­
bin are also released into plasma during the process of muscle cell necrosis. 
Rowland pleads against the term rhabdomyolysis as it does not distinguish 
between mild exertional muscle injury with moderate serum creatine kinase 
(CK) elevation and frank attacks of myoglobinuria.8 He proposes to keep the 
term myoglobinuria and to make a distinction between the general state of 
muscle damage and the acute attack of muscle necrosis, analogous to the dis­
tinction between angina pectoris and myocardial infarction. 
In literature no strict criteria have been met for the diagnosis of rhabdomyoly­
sis, probably due to the diversity of its clinical presentation. In most case 
reports the diagnosis is based upon the following clinical and biochemical fea­
tures: 
ι. An event of muscle destruction with signs and symptoms confined to the 
muscles or with involvement of other systems, resulting in general malaise 
or specific organ diseases such as cardiopathy, neuropathy, encephalopathy 
or nephropathy. 
2. An increase in serum levels of skeletal muscle enzymes, particularly of 
serum creatine kinase (CK). The height of the serum CK level is rather arbi-
tary, but should be at least five fold the normal value.9 
3. An increase in serum level of myoglobin and the presence of urinary myo­
globin. 
Pathophysiology 
Rhabdomyolysis is the result of a direct muscle injury or an altered relation­
ship between energy production and energy consumption in muscle. The 
development of muscle cell necrosis is suggested to start at the plasma mem­
brane, including sarcolemma and T-tubule, where several ΑΤΡ-consuming 
transport systems of electrolytes are located (FIGURE I) . 
There is evidence that the calcium homeostasis, i.e. the balance between the 
intra- and extracellular Cax+-concentration is of crucial importance for the 
integrity of the muscle cell.10 In the intact muscle fibre, there is a steep Ca2+-
22 
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gradient across the plasma membrane, the extracellular Ca2+-concentration 
being a manyfold higher than the intracellular concentration. The binding of 
Ca2+ to a large number of metabolites with a high affinity is one efficient 
mechanism to keep the intracellular free calcium concentration at low levels.11 
The importance of the Na+/K+-pump for the calcium homeostasis and mus-
cle cell integrity has been emphasized by Knöchel.12 The NaVK+-pump at the 
plasma membrane regulates the active transport of Na+ out of the cell and K+ 
into the cell. The activity of this pump appears to be regulated by sodium-
potassium-activated adenosine triphosphatase (Na+/K+-ATPase) and is depen-
dent on sufficient ATP-supply. When the Na+/K+-pump dysfunctions, because 
of energy depletion or direct injury to the plasma membrane, there will be an 
influx of sodium, chloride and water into the cell. An osmotic swelling then 
will lead to muscle cell injury. Subsequently, an exchange of sodium for cal-
cium ions via a protein carrier exchange mechanism promotes an increased 
influx of calcium ions across the membrane, contributing to further muscle 
injury. 
Another way of maintaining the cytoplasmic free calcium concentration 
under control is the effect of the calcium transporting systems. Plasma mem-
branes contain three Ca2+-transporting systems: a Ca2+-channel, a specific 
Ca2+-ATPase and a NaVCa2+-exchanger (FIGURE I) . A pathological increase of 
the influx of Ca2+-ions into cytosol may be attributed to several etiological 
factors. The working hypothesis, suggesting a common terminal sequence of 
events during muscle cell necrosis of whatever origin, has been proposed by 
Wrogemann and Pena.13 The authors believe that initially a generalized plas-
ma membrane defect or a disturbance in the Na+/K+-pump activity allows an 
increased net influx of Ca2+ into the cell. The influx of Ca2+ will set in motion 
cascades of events eventually resulting into muscle cell necrosis. 
Calcium ions are sequestered by the sarcoplasmic reticulum (SR), that con-
tains different Ca2+-transporting systems for the uptake of Ca2+ and the 
release of Ca2+ back to the cytosol (FIGURE I). But once the integrity of the 
muscle membrane and SR membrane have been lost, an increased influx of cal-
cium ions will overload the mitochondria. The mitochondria have an impres-
sive total capacity for Ca2+-uptake and will store away the excess Ca2+ for a 
relatively long time. However, when the level of mitochondrial Ca2+-loading 
has become intolerable to these organelles, the excess Ca2+ will be released 
from mitochondria into cytosol. The functional and structural damage of the 
mitochondria and the ensuing lack of energy will create a vicious cycle as less 
energy becomes available for pumping calcium out of the cell (FIGURE 2). 
24 
A REVIEW OF LITERATURE 
inadequate substrate 
supply 
enzyme 
deficiency 
hypokalemia embolia, compression 
hypokalemia, 
Hypernatremia, 
hyperosmal state 
sickle cell trait 
shock 
alcohol 
enzyme deficiency, 
toxins 
mechanic destruction 
frost, burning, electricity 
FIGURE 2. Schematic representation of the process of muscle cell necrosis and its 
causative factors. 
*5 
CHAPTER 2 
The elevated level of intracellular calcium activates phospholipase A2 resulting 
into the accumulation of lysophospholipids in the muscle cell and raises the 
activity of neutral proteases to a level at which they become destructive to the 
muscle cell. The elevated cytoplasmic Caz+-level will enhance the interaction 
of actine and myosine filaments leading to myofibrillar hypercontracturcs 
and, if the Ca2+-level is critically high, to damage of the muscle cell.14 
Biochemical features 
Rhabdomyolysis is associated with an increased level of myoglobin, CK and 
other muscle cytosolic compounds. 
Myoglobin 
Myoglobin functions as an oxygen store and is an oxygen carrier important in 
maintaining the ability of red muscles to consume oxygen and to generate 
contraction. This small protein of 17,800 kDa is rapidly filtered through the 
renal glomeruli. Myoglobin enters the urine when the plasma concentration 
exceeds 15 mg/1 and will produce dark red-brown urine when urine myoglo-
bin exceeds 1 g/1.'5 A rise in serum myoglobin level (normal 3-80 |ig/l) pre-
table | . Diagnostic discrimination of pigmenturias. 
Myoglobinuria Hematuria Hemoglobinuria Porphyria 
URINE 
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after 
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-
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cedes an increase in serum ск. The concentration of myoglobin in serum 
returns to normal ι to 6 hours after cessation of muscle injury, due to the 
rapid clearance of myoglobin by both renal excretion and metabolism to bili­
rubin.'5 Therefore determination of myoglobin in serum and urine is helpful 
only for the early diagnosis of rhabdomyolysis and the absence of elevated 
levels of serum myoglobin does not eliminate the diagnosis of rhabdomyolysis. 
Pigmenturia may also occur in patients with hemoglobinuria or porphyria, 
but the clinical presentations are different. A diagnostic procedure for differ­
entiating pigmenturia is given in TABLE I. The combination of a positive 
orthotoluidine test, gold-brown pigmented casts in urine, the absence of 
erythrocyturia, colourless scrum and normal haptoglobin level confirms the 
diagnosis myoglobinuria. The method of absorption spectrophotometry is 
not reliable enough for the identification of myoglobin. Immunologic tech­
niques using specific antibodies against myoglobin are the most sensitive tests 
to measure myoglobin in serum and urine. Radioimmunoassay and enzyme-
linked immunoassay have a sensitivity high enough to measure normal con­
tents of myoglobin in serum and urine.'6 
Serum creatine kinase (ск) 
The most suggestive laboratory abnormality in rhabdomyolysis is an elevated 
level of serum CK, at least fivefold the normal value, ск plays an important 
role in the metabolism by catalyzing the reversible transfer of the terminal 
phosphate group of adenosine triphosphate to creatine to form phosphocrea-
tine. Destruction of about 200 gram muscle causes an elevated level of serum 
ск. 
Human tissues contain three isoenzymes of ск: мм, мв and вв. The predom­
inant sources of CK-MM isoenzyme are skeletal and cardiac muscle. The ск-вв 
isoenzyme is found in brain tissue and ск-мв isoenzyme mainly in cardiac, 
but also in skeletal muscle. In rhabdomyolysis, an elevation of total ск, espe­
cially of CK-MM isoenzyme is found, accompanied by an increase of myoglo­
bin in plasma and presence in urine. Involvement of myocardium is likely if 
the isoenzyme ск-мв exceeds 5% of the total ск activity.17 If both the myocar­
dium and the striated muscles are involved, total ск and ск-мв values may be 
difficult to interpret and an ECG may help in the differential diagnosis. 
Serum ск concentration begins to rise 2 to 12 hours after onset of muscle inju­
ry, peaks in 1 to 3 days and declines within 3 to 5 days after muscle injury 
ceases. Serum ск levels remain elevated longer than myoglobin levels because 
of the relatively slow plasma clearance with a serum half-life of about 1,5 days. 
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Persistently and moderately elevated serum ск levels are also present in many 
common myopathies and other disorders, including hypothyroidism, but not 
accompanied by massive muscle necrosis with pigmenturia. The increase of 
serum ск level in acute attacks of rhabdomyolysis is transient and may reach a 
level of 100,000 iu/1, being manyfold higher than in most other conditions. 
Carbonic anhydrase ill 
For diagnostic purposes, serum ск and myoglobin are generally used to dem­
onstrate skeletal muscle damage in rhabdomyolysis. Carbonic anhydrase III is 
an even more specific marker of skeletal muscle injury than are myoglobin 
and serum ск, as it is not present in myocardium.18 The measurement of 
serum carbonic anhydrase III by specific radioimmunoassay is considered a 
practical method for demonstrating skeletal muscle damage in patients with 
rhabdomyolysis.19 
Potassium, calcium, phosphate 
When the integrity of muscle cell membrane is disrupted, the leakage of its 
cellular contents is not restricted to myoglobin and serum ск. Other protein 
and non-protein cellular components are also released into the circulation. 
Important biochemical findings in rhabdomyolysis include hyperkalemia, 
hypocalcemia and hyperphosphatemia. Muscle necrosis of about 150 g will 
release more than 15 mmoles potassium, sufficient to elevate acutely plasma 
and extracellular fluid potassium concentration.9 The resulting hyperkalemia 
increases the risk of cardiac dysrhythmias. Hypocalcemia in the initial phase 
of rhabdomyolysis has been attributed to deposition of calcium salts in 
necrotic muscles.20 Studies have suggested that this results from the release of 
large amounts of organic and inorganic phosphate into the circulation, elevat­
ing the calcium-phosphate product with subsequently deposition of calcium 
salts into tissues and muscles.20 Soft tissue calcification has been demonstrat­
ed by x-ray in necrotic limb muscles during the hypocalcémie phase.20 
Another cause of the initial hypocalcemia may be a fall in plasma levels of 
1,25-dihydroxycholecalciferol, due to hyperphosphatemia.21 During the later 
stage, an excessive rise in calcium may occur, when calcium is mobilized from 
damaged muscles again. Another cause of hypercalcemia has been attributed 
to a secondary hyperparathyroidism, triggered by hyperphosphatemia.14'22 
Other laboratory findings include elevated serum levels of aminotransferases, 
aldolase, lactate dehydrogenase, creatinine, urea, hydroxybutyrate and uric 
acid. Hyperuricemia is the result of enhanced cellular release of purine pre-
28 
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cursors, which are converted to uric acids by the liver. The uric acid concen­
tration in general is correlated to the serum ск level.14 
Case report 
A 23 year old male was admitted to the coronary care unit of the hospital with 
a cardiac arrest, severe muscular weakness and dyspnea. He had a one week 
history of flu-like headache, myalgia and fever. During the episode of nonspe­
cific febrile disease no drugs were used. His urine was dark coloured and the 
urine output had become scanty. His previous medical history included at 
least two episodes of similar complaints, preceeded by nonspecific febrile dis­
eases. He had no muscle symptoms related to exercise or fasting. 
On admission the patient was drowsy and dyspnoic. Body temperature had 
become normal again. There was a generalized muscular weakness and ten­
don areflexia. Swelling of the muscles of the lower and upper extremities was 
accompanied by moderate myalgia. Laboratory data indicated severe rhab-
domyolysis with elevated levels of serum ск to 11,176 iu/1 (normal 15-91), 
serum myoglobin to 6,800 mg/1 (normal< 85), ASAT to 79 iu/1 (normal 7-25) 
and А1АТ to 204 iu/1 (normal 5-25). In addition he had severe disturbances of 
plasma electrolytes and renal impairment: sodium 128 mmol/1 (normal 139-
147), potassium 8.4 mmol/1 (normal 3.7-4.6), calcium 1.26 mmol/1 (normal 
2.30-2.80), urea 63 mmol/1 (normal 2.9-6.5) and creatinine 1,089 Mmol/1 (nor­
mal 80-110). The urine production was less than 500 cc/24 hours, the urine 
was dark coloured and contained myoglobin in a concentration of 1,050 mg/1. 
The patient was treated with hemodialysis and he gradually recovered. The 
levels of serum ск and transaminases gradually declined within two weeks. 
To determine the etiology of the recurrent rhabdomyolysis a standardized 
ischemic fore-arm test was performed.23 A normal rise of venous lactate and 
ammonia made the presence of myophosphorylase deficiency or myoadeny-
late deaminase deficiency very unlikely. In leukocytes the activities of carni­
tine palmitoyltransferases 1 and 11 were normal. The level of serum carnitine 
was normal as well. 
A biopsy from the quadriceps muscle was taken. There was no evidence of 
infection histologically and no virus could be isolated from muscle culture. 
Histological study of muscle biopsy showed necrotic and atrophic fibers (FIG­
URE 3). The number of fibers with internal nuclei had increased to 23-37% 
(normal< 3). Histochemically, myoadenylate deaminase activity was normal. 
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FIGURE 3. Muscle cell necrosis surrounded by muscle fibres with a variety of muscle 
diameter. Bar = 50 Um. 
Glycogen and fat content were normal. Electron microscopic examination 
showed no additional abnormalities. 
Biochemical studies of muscle homogenate revealed no disturbance in lipid 
and glycogen metabolism. The pyruvate oxidation rate was normal. The 
activities of Phosphorylase, phosphofructokinase, carnitine palmitoyltransfe­
rase 1 and и and cytochrome-c-oxidase were normal. The levels of carnitine 
and cytochrome complexes were normal as well. 
In his family his father and one brother also suffered from recurrent attacks of 
rhabdomyolysis, each of them preceeded by a viral febrile disease. In between 
these attacks of rhabdomyolysis, serum с к level was repeatedly elevated in the 
patient, his father and his brother. The recurrence of the rhabdomyolytic 
attacks and the identical symptoms in his brother and father are suggestive of 
an autosomal dominant inherited disorder, but a not yet revealed metabolic 
defect. 
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In this patient no etiological cause for his rhabdomyolysis could be found. In 
the affected brother of this patient, however, a disturbance in the calcium 
homeostasis in cultured myotubes was found.24 In the presence of extracellu­
lar calcium the basal concentration of cytosolic free calcium rose to an abnor­
mal high level as compared to controls.24 
Clinical aspects 
There is a great heterogeneity in the clinical presentation of rhabdomyolysis, 
which is probably due to the diversity of the etiological factors. The clinical 
features can be divided into: a. muscular signs and symptoms accompanied by 
pigmenturia, b. general internal disturbances, с complications resulting from 
involvement of other organ systems. 
Muscular signs and symptoms consist of muscle pain, tenderness, stiffness, 
contractures, and weakness. In most case reports the muscle pain, weakness 
and swelling are emphasized, but in Gabow's study only fifty percent of the 
patients with rhabdomyolysis presented with muscular signs and symptoms.9 
Rhabdomyolysis may involve all striated muscles diffusely or focus on certain 
groups of muscles. Usually the postural muscles of thighs, calves and the 
lower back and the muscles of the arms are painful and weak. When edema 
develops, the muscles become stiff and tender to palpation. Muscle swelling 
of the calves can result into hard contractures and loss of ankle jerks. Rhab­
domyolysis can also extent to the muscles of chest, abdomen, palate and 
throat and the masticatory muscles. In general the muscle repair mechanisms 
seem to function extremely well, as the permanent damage to muscle that 
results from both traumatic and nontraumatic events is surprisingly minimal. 
Usually, the muscle disorder is selflimiting and leads to complete recovery 
within days or weeks. 
General internal disturbances may be prominent in fulminant rhabdomyolysis, 
leading to general malaise, fever, tachycardia, stomach ache, nausea and vom­
iting. High levels of urea may result into encephalopathy with diminished 
consciousness, agitation and confusion. Depression of cerebral metabolism is 
followed by inadequate ventilation, leading to hypoxia and respiratory acido­
sis. 
The major complications of rhabdomyolysis resulting from involvement of 
other organ systems are cardiac arrest, compartmental syndrome and acute 
renal failure. 
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Fulminant rhabdomyolysis associated with severe hyperkalemia and hypocal-
cemia may induce a life-threatening complication of cardiac arrest. Hyperkale-
mia has a cardiotoxic effect which may be potentiated by hypocalcemia. Cor-
rection of hyperkalemia is accomplished by administration of a potassium 
exchange resin. Infusion of calcium salts to counteract the effects of hyperka-
lemia is not recommended in the presence of hyperphosphatemia, as it may 
cause calcium phosphate deposition in soft tissue. 
The development of the compartmental syndrome is another reported compli-
cation of rhabdomyolysis. In significant rhabdomyolysis the muscle swelling 
may produce compression of the adjacent vessels and nerves within the tight 
fascial compartments. When the compartmental pressure exceeds the prevail-
ing arterial pressure, secondary ischemic necrosis and muscle destruction will 
be the result. Compartmental syndrome in non-traumatic rhabdomyolysis is 
usually subsequent to prolonged coma or immobilization following overdose 
of various drugs. The patient's own body weight can raise the external press-
ure on muscles. The direct toxicity of alcohol and heroin on muscles is very 
likely to be of etiological importance as well. The treatment of choice in com-
partmental syndrome is urgent fasciotomy. Nerves are damaged by external 
pressure, ischemia and increased intracompartmental pressure. Tissue press-
ure measurements possibly aid in the decision of whether or not surgical 
intervention is indicated. If the interstitial muscular pressure during 8 hours 
exceeds 35 mm Hg, fasciotomy is recommended to relieve pressure and pre-
vent nerve damage. 
A major threat and the most frequently reported complication of rhabdomyo-
lysis is acute renal failure. The frequency of acute renal failure in rhabdomyo-
lysis is not known, but it occurred in about one third of the patients in 
Gabow's study.9 Rhabdomyolysis is said to be an etiologic factor in 5-7% of 
cases of acute renal failure.25 It is not clear why this complication develops in 
some patients and not in others. Some authors have the experience that acute 
renal insufficiency develops often in patients who are also compromised in 
some other way that influences renal function.26 Other observations refer to 
the large muscle mass in highly trained persons who are capable of releasing 
larger quantities of myoglobin into the circulation. The exact pathogenesis of 
myoglobinuric acute renal failure has not been clarified. The major theories 
that have been advanced to explain its development include both factors relat-
ed to renal circulation as well as factors related to direct tubular injury: 
- Backleak of filtrate through the damaged tubular epithelium to the peritu-
bular circulation.27 
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FIGURE 4· Medullary zone of the kidney stained with antibodies to myoglobin. 
Myoglobin is present in the lumen (A) and in the epithelial cells of the 
renal collecting tubules (в). There is no staining in the erythrocytes in 
figure в (arrow). 
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- Renal ischemia as a result of vasoconstriction of renal arterioles. 
- Associated shock with impaired renal flow and decreased glomerular filtra-
tion rate. 
- Tubular obstruction by precipitation of pigmented casts in the ultra filtrate. 
- Tubular injury by direct toxicity of myoglobin in itself or indirect by the 
heme pigments released from myoglobin in the presence of hypovolemia 
and aciduria (FIGURE 4).28,29 
- Release of neutral proteases or vasoactive kinins from injured skeletal mus-
cle cells that may directly damage the kidney.30 
Maintenance of adequate circulating blood volume is critical in the preven-
tion of acute tubular necrosis. Administration of 4 to 11 liters of normal saline 
solution intravenously may be necessary to maintain blood pressure and urine 
output. Volume expansion is essential to increase urinary output and to dilute 
the concentration of myoglobin. Knöchel recommends an infusion of furose-
mide in a dose of 40 to 120 mg in 100 ml, 25% mannitol solution.12 Because 
acidic urine favors myoglobin nephrotoxicity, alkalinization of the urine by 
adding sodium bicarbonate to the intravenous fluids has been advocated.31 
The use of sodium bicarbonate however is controversial as very large quan-
tities of bicarbonate may aggravate hypocalcemia.12 If oliguria persists and 
medical treatment has not been sufficient to overcome renal failure, dialysis 
may be necessary to manage hyperkalemia or volume overload. Uremic 
encephalopathy can be an indication as well. Hemodialysis restores fluid and 
electrolyte balance more quickly than peritoneal dialysis. 
Classification 
The categories of rhabdomyolysis may be divided into traumatic and non-
traumatic forms or classified to endogenous and exogenous causes. A func-
tional classification can be made to divide rhabdomyolysis into hereditary and 
acquired forms. Any classification however has its limitations, as there is often 
more than one cause in each attack of rhabdomyolysis. In some cases genetic 
causes overlap with non-genetic causes. Recurrent attacks of rhabdomyolysis 
in patients with hereditary enzyme defects are usually induced by exercise. 
But also in patients with an acquired rhabdomyolysis, exercise may be the 
trigger. Rhabdomyolysis due to drug-induced coma may also be related to 
trauma, immobilization, hypoventilation, shock, metabolic acidosis and seve-
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ral other factors. In the study of Tonin et al the attacks of rhabdomyolysis in 
patients with hereditary enzyme defects usually occurred repeatedly; but also 
patients without defined enzyme defects were likely to develop multiple epi­
sodes of rhabdomyolysis, suggesting that most of them also had inherited but 
not yet identified disorders.6 
Hereditary causes of rhabdomyolysis 
Hereditary causes of rhabdomyolysis include inherited disorders of glycogen 
and lipid metabolism, other genetic diseases such as malignant hyperther­
mia,5 and endogenous disorders with not yet revealed causes, commonly 
denominated as idiopathic rhabdomyolysis (TABLE 2).3 In hereditary rhab­
domyolysis the number of recognized metabolic defects has increased during 
the last two decades. Tonin et al evaluated the muscle biopsies of 77 patients 
with idiopathic rhabdomyolysis and found specific enzyme defects in about 
half of the patients. 6 Most patients had one or more episodes of rhabdomyo­
lysis. 
table 2. Causes of hereditary rhabdomyolysis. 
Deficiencies of glyco(geno)lytic enzymes and mode of inheritance: 
myophosphorylase (McArdle's disease) 
Phosphorylase kinase 
phosphofructokinase (pFic)(Tarui's disease) 
phosphoglycerate kinase (PGK) 
phosphoglycerate mutase (PGAM) 
lactate dehydrogenase (LDH) 
Abnormal lipid metabolism 
autosomal recessive, rarely AD 
autosomal recessive 
autosomal recessive 
x-linked recessive 
autosomal recessive 
autosomal recessive 
carnitine palmitoyltransferase deficiency (CPT) I and 11 
carnitine deficiency 
Various genetic disorders 
idiopathic rhabdomyolysis 
myoadenylate deaminase (MAD) deficiency 
malignant hyperthermia (мн) 
neuroleptic malignant syndrome (NMS) 
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glycogen Phosphorylase kinase 
myophosphorylase 
glucose-i-p 
Î 
glucose-6-p 
\ 
fructose-6-p 
phosphofructokinase (PFK) 
fructose-i,6-p 
Í 
glyceraldehyde-3-p y 
ι, 3-d iphosphoglycerate 
phosphoglycerate kinase (PGK) 
3-phosphoglycerate 
phosphoglycerate mutase (PGAM) 
2-phosphoglycerate 
Î 
phosphoenolpyruvate 
I 
pyruvate 
lactate dehydrogenase (LDH) 
lactate 
FIGURE 5. Glyco(geno)lysis and the sites of the metabolic block due to deficiency of 
glyco(geno)lytic enzymes. 
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Recurrent rhabdomyolysis is a characteristic of a number of inherited glyco­
gen storage diseases of muscles. The defective enzymes of glyco(geno)lysis 
that have been identified in relation to rhabdomyolysis are myophosphoryl-
ase, Phosphorylase kinase, phosphofructokinase (PFK), phosphoglycerate 
kinase (PGK), phosphoglycerate mutase (PGAM) and lactate dehydrogenase 
(LDH). The sites of the metabolic block due to deficiency of glyco(geno)lytic 
enzymes are represented in FIGURE 5. Exercise is virtually the most important 
triggering factor in patients with glyco (geno) lytic enzyme defects. The meta­
bolic block in glygo(geno) lysis causes a disturbance in the energy production 
early during intensive exercise. When there is not sufficient fuel to regenerate 
high-energy compounds, ATP levels fall below a critical level, resulting in loss 
of integrity of membranes and muscle necrosis, especially of the type 2 fibres 
which depend primarily on glycolysis.32 Exercise intolerance, muscle cramps 
and pigmenturia are the main symptoms in glyco (geno) lytic disorders. In 
most patients the first symptoms start before the age of 20, and the attacks of 
rhabdomyolysis are intermittent and exercise-induced. In glyco(geno)lytic 
disorders the mode of inheritance is usually autosomal recessive, except for 
PGK deficiency which is x-linked. Serum ск level is persistently increased to a 
level of 5 to 10-fold the normal value. During the ischemic fore arm test, when 
the patient performs intensive squeezing with one hand, the normal rise of 
lactate in venous blood is very small or completely absent.2' In muscle biopsy 
histological examination shows an accumulation of glycogen beneath the sar-
colemma and enzyme-histochemically the staining for the glyco(geno)lytic 
enzyme is negative. The activity of the individual glyco(geno)lytic enzymes 
and their content can also be measured in muscle biopsy. 
Myophospborylase deficiency (McArdle's disease) has been known since 1959." 
The exercise-intolerance is most prominent during the first то minutes of 
intensive exertion. After taking a brief rest the patient can resume exercise; 
this so called second wind phenomenon proved to be very characteristic of 
myophosphorylase deficiency.333 We reviewed 120 reported cases of McArdle's 
disease in literature from 1951 till 1987 and studied them on the items of rhab­
domyolysis and precipitating factors, ск levels, myoglobinuria and acute renal 
failure. In 44 reports 62 case histories were documented well enough on these 
items for evaluation. The total number of the Dutch McArdle patients that 
were known in 1988 in the university centers was 20 and included 2 children 
and 18 adults (unpublished observation). Informed consent was obtained 
from these 20 patients to review their medical charts. Dutch data were in 
accordance with those from literature. In 56% of the patients in literature and 
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in 75% of the Dutch patients overt myoglobinuria and an elevated serum CK 
level was present, indicative of rhabdomyolysis. In half of all the patients the 
rhabdomyolytic attacks occurred once or twice, in the other half more fre-
quently. Exercise was the main precipitating factor in all patients. Acute renal 
failure developed in 8% of the patients in literature and in 6% of the Dutch 
patients, who eventually all recovered well. One major difference between the 
patients of literature and the Dutch patients concerns the presence of the sec-
ond wind phenomenon. The second wind phenomenon in literature is men-
tioned present in 24 patients (39%), but in 38 (61%) of the patients probably 
not inquired after. In 18 of 20 Dutch patients (90%) the second wind phe-
nomenon was obviously present. This may be attributed to the careful medi-
cal history that was taken from the patients. 
Tonin et al. screened the biopsies of 30 patients with exercise-intolerance 
without myoglobinuria and found myophosphorylase deficiency in 17 of them 
(58%) .6 Therefore, as myoglobinuria does not prove to be an obligatory con-
sequence of McArdle's disease, many patients with only exercise-intolerance 
may not be identified as McArdle patients. McArdle's disease is, after carnitine 
palmitoyltransferase deficiency, the second common disorder of muscle 
metabolism causing exercise-induced rhabdomyolysis. 
Phosphorylase kinase deficiency, known as a cause of benign hepatomegaly in 
infancy, has rarely been reported in relation to rhabdomyolysis.34 However, in 
the 77 muscle biopsies of patients with rhabdomyolysis, Tonin found a Phos-
phorylase kinase deficiency in four of them.6 She concluded that the impor-
tance of this enzyme defect as a cause of rhabdomyolysis has been underesti-
mated. 
Phosphofructokinase (PFK) deficiency (Tarui's disease) has been known since 
1967,35 and only been related to rhabdomyolysis with pigmenturia in a few 
cases, as reviewed by DiMauro.36 The clinical picture is identical to that of 
muscle Phosphorylase deficiency: a life-long intolerance to strenuous exercise 
with pain and stiffness of exercising muscles. However, a few cases of PFK defi-
ciency have been reported starting at old age with progressive limb weakness 
and should therefore be considered in the differential diagnosis of late-onset 
myopathy.6 
Three defects of terminal glycolysis, phosphoglycerate kinase deficiency, 
phosphoglycerate mutase deficiency and lactate dehydrogenase deficiency 
were described between 1980 and 1983.37'38 
Phosphoglycerate mutase (PGAM) deficiency and Uctate dehydrogenase (LDH) defi-
ciency are clinically characterized by exercise-intolerance, muscle cramps and 
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recurrent rhabdomyolysis, but with no fixed weakness. They may not have 
been identified earlier because they do not cause a complete block, of the gly­
colytic pathway and do not result in severe glycogen accumulation in muscle 
biopsy. 
Phosphoglycerate kinase (PGK) deficiency has been first described by DiMauro 
in a 14 year-old boy with rhabdomyolysis and renal failure after intense exer­
cise.38 The enzyme defect is also expressed in erythrocytes, in fibroblasts and 
muscle cultures, PGK deficiency is an x-linked recessive trait and usually asso­
ciated with hemolytic anemia, mental retardation and seizures. 
Several therapies have been tried to improve the exercise tolerance in 
glyco(geno)lytic disorders and to prevent attacks of rhabdomyolysis. Oral 
supply of glucagon or glucose has no longlasting effect. In PFK deficiency glu­
cose has a negative effect on exercise-tolerance as it can not be used as energy 
supply and even impedes lipolysis. Wagenmakers et al. suggested that espe­
cially physical training would stimulate the mitochondrial oxidative processes 
and improve exercise tolerance in myophosphorylase deficiency.40 
Recurrent rhabdomyolysis is also a characteristic feature of carnitine palmi­
toyltransferase (СРТ) I and 11 deficiency, a disorder of lipid metabolism, CPT I 
and π deficiency, first described in 1973 by DiMauro,41 proved to be the most 
common hereditary disorder causing rhabdomyolysis in the cases studied by 
Tonin.6 CPT 1 and 11 are responsible for the transport of long-chain fatty acids 
across the mitochondrial membrane, for which process the fatty acids first 
have to be esterified with carnitine. In patients with CPT I and и deficiency, 
muscle pain and rhabdomyolysis develop after strenuous exercise for a pro­
longed time without adequate intake of food or during prolonged stress. This 
is in contrast to the development of rhabdomyolysis in glyco(geno)lytic disor­
ders, where it occurs in the initial phase of exercise. In CPT I and 11 deficiency, 
attacks of rhabdomyolysis can be succesfully prevented by maintenance of 
adequate intake of carbohydrates during long periods of exercise. 
The frequency of rhabdomyolysis in CPT deficiency is in sharp contrast with 
its rarity in mitochondrial myopathies,42 acid maltase deficiency'6 and in 
systemic carnitine deficiency.43 Deficiency of CPT results in recurrent rhab­
domyolysis, while deficiency of the substrate carnitine predominantly causes 
lipid storage myopathy.43 The reason for this difference in clinical presenta­
tion is not clear. Recurrent attacks of rhabdomyolysis have been described in 
only 3 patients with myopathic carnitine deficiency,44·45,46 and in one patient 
with a secondary carnitine deficiency syndrome due to long-chain acyl-CoA 
dehydrogenase deficiency.47 
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Idiopathic rhabdomyolysis or paroxysmal paralytic myoglobinuria, has been 
frequently reported in the earlier case reports before 1980, when an number of 
inherited enzyme defects had not yet been described. The first recorded case 
of idiopathic rhabdomyolysis is credited to Meyer-Betz, whose name often 
has been linked with rhabdomyolysis of unknown etiology.5 In 1959 Korein, 
Coddon, and Mowrey reviewed all those cases recorded as idiopathic paroxys­
mal myoglobinuria.48 They suggested that two main types could be differen­
tiated. In the first, type I, the disease appeared to be precipitated by exertion, 
and the second, type II, was usually associated with or preceeded by an infec­
tion. Korein suggested that type 1 should be called exertional myoglobinuria 
and type 11 toxic myoglobinuria. Savage et al. concluded from their study that 
exertional rhabdomyolysis type ι is predominantly found in adolescents, 
whereas the toxic type 11 is more often seen in young children.49 Since an 
increasing number of inherited enzyme deficiencies have been characterized 
as a cause of rhabdomyolysis during the past two decades, most of these earli­
er case reports are now presumed to have had an unknown metabolic etiology. 
MyoadenyUte deaminase (MAD) deficiency has first been described in 1978 in 5 
patients with exertional myalgia.50 MAD is involved in purine nucleotide 
breakdown by catalyzing the irreversible deamination of adenosine mono­
phosphate to inosine monophosphate while ammonia is being formed. This 
reaction chain is active during muscle activity, especially during ischemic 
exercise. The clinical features are rapid fatigue and weakness or cramping fol­
lowing vigorous exercise. In some cases exertional rhabdomyolysis has been 
described.5°·51·52 As MAD deficiency has often been associated with other well-
defined disorders, e.g. amyotrophic lateral sclerosis,52 hypokalemic periodic 
paralysis,53 dermatomyositis,54 and progressive systemic sclerosis,55 a coinci­
dental association of MAD deficiency with other causes of rhabdomyolysis can 
not be excluded. Although its pathogenetic significance in muscle disorders 
has not been disclosed,55* yet myoadenylate deficiency does impair energy 
production.13 In the study of Tonin et al. in 3 patients with rhabdomyolysis an 
isolated MAD deficiency was found. 
In addition to metabolic causes, recurrent rhabdomyolysis has been attributed 
to a number of incompletely characterized genetic defects. Recently a defect 
of the mitochondrial energy-transducing system due to multiple deletions of 
mitochondrial DNA has been reported as a novel cause of inherited recurrent 
rhabdomyolysis in 2 brothers.56 
Malignant hyperthermia (мн) is the most life-threatening form of rhabdomyo­
lysis.57 ΜΗ is characterized by a hypermetabolic state of the skeletal muscle, 
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associated with extreme muscle rigidity and rhabdomyolysis, rapidly rising 
body temperature to 4i°C, metabolic acidosis, cardiac arhythmia and dis­
seminated coagulopathy. The genetic defect is presumed to affect the ryano­
dine receptor or the Cai+-release channel where an idiopathic increase of cal­
cium ions seems to play an important role in the pathomechanism.57 The 
syndrome is almost always observed after administration of volatile anesthet­
ics, e.g. halothane, and depolarising muscle relaxants such as succinylcholine. 
A combination of cooling, hydration and intravenous administration of dan­
trolene sodium are the therapy of choice and may avoid a lethal catastrophe. 
Additionally, isolated episodes of rhabdomyolysis have also been induced by 
physical or emotional stress.5,58 
The clinical manifestations of malignant hyperthermia are almost identical to 
the neuroleptic malignant syndrome (NMS). Patients receiving neuroleptics may 
also develop a potentially lethal disorder, characterized by moderate hyper­
thermia, instability of the autonomic nervous system, muscle rigidity, and 
myoglobinuria accompanied by an increase in serum CK.59 All kinds of neuro­
leptic medication, including synthetic narcotics and tricyclic antidepressants, 
may induce NMS. 6° As hyperthermia and rhabdomyolysis respond well to 
dantrolene sodium therapy in both мн and NMS, some have suggested a simi­
lar underlying defect triggered by halothane or neuroleptics.61 Different from 
мн, however, is the gradual development of signs and symptoms in NMS. 
Another difference is the central disorder in NMS and the presumed sarcolem-
mal defect in м н . б і а 
Non-hereditary or acquired causes of rhabdomyolysis 
The majority of patients that develop rhabdomyolysis have no underlying 
neuromuscular disease, but are exposed to unusual circumstances, including 
extreme exhaustion, trauma or ischemia to muscle or exposure to drugs and 
toxins. The causes of non-hereditary or acquired rhabdomyolysis are numer­
ous and diverse (TABLE 3). Genetic susceptibility is not considered to be 
responsible for the development of rhabdomyolysis: anyone who is stressed 
sufficiently, is exposed to drugs or toxins, or suffers from metabolic disorders 
or infectious diseases, may develop rhabdomyolysis. 
Chronic myopathy with acute rhabdomyolysis was first described in a series 
of reports by Fahlgren and colleagues in patients with alcohol abuse (от many 
years.62 In large series of patients with rhabdomyolysis,9'63 chronic alcoholism 
and drug abuse appear responsible for the majority of cases of rhabdomyoly­
sis. Ethanol itself may have a direct toxic effect on muscles,64 or interfere with 
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tabic 3. Causes of acquired rhabdomyolvsis. 
Toxic 
alcohol 
drugs and toxins (see TABLE 4) 
Excessive muscle exercise 
sports 
military training 
status epilepticus 
status asthmaticus 
convulsions 
prolonged myoclonus 
acute dystonia 
Direct muscle injury 
crush 
burning 
freezing 
electric shock 
lightning stroke 
prolonged immobility 
Ischemic injury 
compression 
vascular occlusion 
sickle cell trait 
Metabolic disorders 
diabetic ketoacidosis 
nonketotic hyperosmolar coma 
hypothyroidism 
hypophosphatemia 
hyponatremia 
hypokalemia 
Infections 
viral 
bacterial 
Heat related syndromes 
toxic shock syndrome 
heat stroke 
Inflammatory myopathies 
polymyositis 
dermatomyositis 
Other 
anticholinergic syndrome 
acute L-Dopa depletion syndrome 
muscle metabolism.65 Alcohol may induce acute attacks of rhabdomyolysis 
with pain and swelling of muscles. Different from alcohol-induced rhabdo-
myolysis is the acute hypokalemia myopathy in alcoholics which is character-
ized by rapidly developing muscle weakness without pain or swelling.66 One 
cause of hypokalemia in alcoholics is probably vomiting and diarrhoea. A 
subclinical chronic myopathy may proceed to acute muscle necrosis after a 
sustained period of alcohol abuse and deprivation of food. Involvement of 
the heart muscle, resulting in cardiomyopathy, has been described by Senevi-
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rame.67 Chronic alcoholism causes mainly atrophy of muscle fibers type 2. 
These rapidly contracting fibers are predominantly dependent on glyco-
(geno)lysis for their energy supply.68 The light-microscopic findings in alco-
hol-induced rhabdomyolysis include necrosis and invasion of degenerated 
fibres by leukocytes and macrophages.69 At the structural level there is dilata-
tion of sarcoplasmic reticulum, increased fat and glycogen, and distorted 
mitochondria.64 
Rhabdomyolysis has developed in patients exposed to a great variety of drugs 
and toxins with direct effect on muscle, including heroin,70 cocaine,71 
amphetamine,72 phencyclidine,73 theophylline,74 antihistaminics,75 anti-
hyperlipidaemics,76 barbiturates, antibiotics, beta-blockers and several other 
myotoxic drugs (TABLE 4).77"81 Some drugs and toxins exert a direct toxic 
effect on muscles, but in many types of drug-induced rhabdomyolysis, the 
underlying mechanisms are not clear. Neuroleptics may primarily affect the 
central nervous system or the neuromuscular junction. The abrupt withdraw-
al of L-Dopa medication in parkinsonian patients,82 can lead to clinical fea-
tures similar to NMS and the central anticholinergic syndrome, consisting of 
dry mouth, dilated pupils, urinary retention, increased body temperature and 
rhabdomyolysis. Overdose of certain drugs such as heroin and barbiturates is 
associated with rhabdomyolysis, which may be due to secondary factors like 
muscle compression in coma, delirium and hyperthermia. Rhabdomyolysis 
has frequently been observed after chronic ingestion of compounds and drugs 
associated with hypokalemia, like licorice, carbenoxolone, laxatives and diu-
retics.83,84 
Several case reports of rhabdomyolysis deal with envenomation by snakes, 
hornets, spiders and scorpions containing myotoxins, probably phospholi-
pases, that proved to cause rhabdomyolysis.85 Two large epidemics of acute 
attacks of rhabdomyolysis occurred after ingestion of contaminated fish.86 
Eating of quails, feeded by hellebore or hemlock, has also been associated 
with outbreaks of acute attacks of rhabdomyolysis with fatal outcome.87,88 
From sports medicine it is clear that many cases of rhabdomyolysis are due to 
strenuous exercise, especially in untrained individuals.89 A lack of heat accli-
matization, profuse sweating, insufficient intake of salts and high ambient 
temperature, resulting in hemodilution and hyponatremia, are potentially 
hazardous for the development of rhabdomyolysis.90 
Heat stroke'is a disorder with manifestations of rhabdomyolysis and metabolic 
encephalopathy, anhydrosis and raised body temperature. Heat-related syn-
dromes have been reported in combination with the use of phenothiazines, 
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tobte 4. Drugs and toxins associated with rhabdomyolysis. 
DRUGS 
alcohol 
ethanol 
opiates 
cocaine 
amphetamines 
phencyclidine 
neuroleptics 
barbiturates 
theophylline 
antihistamines 
Clofibrate, bezafibrate 
epsilon aminocaproic acid 
antibiotics 
azathioprine 
amphotericin В 
TOXINS 
tetanus toxin 
typhoid toxin 
staphylococcal toxin 
water hemlock 
sea snake 
hornet venom 
plasmocid 
Haff s fish 
quail 
carbon monoxide 
toluene 
glycyrrhetinate (licorice, 
carbonoxolon) 
succinylcholine 
strychnine 
impairing temperature regulation.91 Heatstroke may develop in older individ­
uals in relation to exhaustion,91 may develop in amphetamine abuse,93 and in 
patients with sickle cell trait.94 All heat-related syndromes may be complicat­
ed by the development of disseminated coagulopathy. 
Extreme muscU activity itself is also a causative factor in pathological condi­
tions, such as general convulsions,95 status epilepticus,96 and status asthmati-
cus,
97
 prolonged myoclonus,98 severe dystonia99 and acute psychosis.100 
Direct muscle injury occurs in crush,101 and ischemic injuries,102 burning, 
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frostbite,105 electric shock or lightning stroke.104 Prolonged immobility dur-
ing surgery,105 and pressure palsies in comatose patients seem also to interfere 
with the energy metabolism of muscles, resulting in rhabdomyolysis. 
Metabolic depression may directly affect muscles or indirectly disturb the ener-
gy metabolism. Diabetic keto-acidosis,106 non-ketotic hyperglycemia107 and 
hypothyroidism IoS are the main anomalies affecting the muscle cell integrity 
or distorting the cellular energy processes. Rhabdomyolysis induced by hypo-
kalemia has been associated with the intake of several medicaments and com-
pounds, but has also been observed in miscellaneous disorders like anorexia 
nervosa,109 Banter's syndrome,110 renal tubular acidosis,111 total parenteral 
nutrition112 and electrolyte disturbance following small bowel resection."3 
Hyponatremia, due to water intoxication, as a cause of rhabdomyolysis has 
been described in a patient with psychogenic polydipsia.114 
Progressive muscle diseases such as polymyositis and dermatomyositis have fre-
quently been associated with rhabdomyolysis."5 Patients with chronic inflam-
matory myopathy seem more susceptible to attacks of rhabdomyolysis."6 
Rhabdomyolysis occurs in a variety of systemic infections,117 and may be relat-
ed to either fever,"8 the effect of toxins or to a direct injury of skeletal muscles 
by infectious agents. Rhabdomyolysis related to bacterial infections include 
reports of typhoid fever,"9 staphylococcus,110 and infection by Shigella, Sal-
monella, Herbicola lathery and E.coli.121 Also Legionnaires' disease,122 leptos-
pirosis,123 and Clostridium perfringens infection have been reported in associ-
ation with rhabdomyolysis. 
Rhabdomyolysis may play a role in the toxic shock syndrome, which is asso-
ciated with staphylococcal toxin and characterized by hypotension, fever, 
encephalopathy, erythematous rash and liver disease and renal failure. 
According to the criteria of Todd et al, at least four organ systems including 
muscle, brain, liver and kidney, have to be involved.124 Influenza is the most 
common trigger for developing viral-induced rhabdomyolysis.125 Yet many 
more viruses have been identified, such as infectious mononucleosis,126 Cox-
sackie,127 herpes,128 adenovirus,129 enterovirus and echoviruses.I3° Recently, 
recurrent rhabdomyolysis in association with human immunodeficiency viral 
infection has been reported.131 
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Diagnostic guidelines 
The diagnostic procedures to be followed depend on the clinical presentation, 
the severity of the muscular signs and symptoms, the presence of complica­
tions and the presumed etiological factors. In general the diagnostic pathway 
can be divided into three main steps: i. confirmation of the diagnosis rhab-
domyolysis and its common pathogenetic factors, 2. estimation of the risk for 
developing acute renal failure and prevention of other complications in the 
acute phase, and 3. further search for an underlying metabolic disorder or 
genetic defect. 
The diagnosis rhabdomyolysis suspected from the patient's muscular signs 
and symptoms can be confirmed by an increased level of serum CK and myo­
globin. In the initial phase the presence of myoglobin in urine can be estab­
lished by radioimmunoassay. 
Careful evaluation of the patient's history and laboratory data will promote 
prompt treatment and minimize the complications associated with rhabdom­
yolysis. Analyses of arterial blood for pH, Р
С О г
 а п
^ ^oz
 s n o u
^ be performed 
and measurement in serum of sodium, potassium, chloride and c o 2 content, 
calcium, phosphate, albumin, uric acid, lactate dehydrogenase, aspartate 
aminotransferase, bilirubin, alkaline phosphatase, urea and creatinine. The 
urinary output and the pH of urine should be measured. Attention has to be 
paid to the most common causative factors of rhabdomyolysis, which include 
alcoholism and drugs, excessive muscle exercise, direct muscle trauma, 
ischemic injury, compression of limbs, derangement of electrolyte balance, 
endocrine dysfunction, infection or inflammatory myopathy. 
When the underlying pathogenesis is not clear, and especially in recurrent 
rhabdomyolysis the patient should be scrutinized for a hereditary or genetic 
disorder of muscle metabolism. Evaluation of the medical history must be 
directed to the familial occurence of muscular symptoms, exercise-tolerance, 
anesthesia-induced muscle problems and the presence of the second wind 
phenomenon. 
Physical examination usually reveals no abnormalities and only rarely slight 
muscle atrophy or weakness. Technical assesment consists of measuring the 
activities of glyco(geno)lytic enzymes in erythrocytes, and of CPT I and 11 in 
leukocytes, the level of serum carnitine and organic acids in urine. An ischem­
ic fore arm test is performed to measure the increase of lactate and ammonia 
in venous blood. Electromyography is only of value in the acute phase of 
rhabdomyolysis when myopathic findings are present. In muscle biopsy light-
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microscopic findings of necrosis of muscle fibres are rather non-specific and 
of little value for the differential diagnosis. Histochemical examination, how­
ever, may reveal glycogen accumulation or increased lipid deposits, indicating 
a glyco(geno)lytic enzyme deficiency or disorder of lipid metabolism. 
Enzyme-histochemical examination can reveal deficiency of glyco(geno)lytic 
enzymes or MAD. Biochemical investigation of muscle biopsy may yield 
important information about carnitine content and CPT I and и activity, oxi­
dation of fatty acids and pyruvate oxidation and mitochondrial metabolism. 
The activity of glyco(geno) lytic enzymes can be measured in muscle biopsy 
biochemically or determined by chromatographic or electrophoretic exam­
ination, or their contents can be determined by immunological methods. 
Final remarks 
Rhabdomyolysis is not rare. The clinical signs and symptoms may vary wide­
ly from mild myalgia to severe muscle weakness with involvement of other 
organ systems. The diagnosis should be confirmed by measuring serum ск 
and myoglobin. The subsequent metabolic disturbances can be life-threaten­
ing factors. Cardiac arrest, acute renal failure and the compartment syndrome 
are the major complications of severe rhabdomyolysis. The etiologic factors of 
rhabdomyolysis are numerous and of diverse origin. Alcoholism, drugs and 
toxins, strenuous exercise, infections and metabolic disturbances are the most 
common etiologies in acquired rhabdomyolysis. In hereditary enzyme defi­
ciencies, exercise is usually the triggering factor. 
The treatment in the acute phase of rhabdomyolysis consists of the mainte­
nance of adequate circulating blood volume and sufficient diuresis to prevent 
renal complications. In acquired recurrent rhabdomyolysis withdrawal of the 
toxic drug or compound is treatment of choice. In case of glyco(geno)lytic 
enzyme deficiency or a disorder in lipid metabolism, advise should be given 
about adequate intake of food in relation to exercise. In мн and NMS dantro­
lene sodium is the medication to prevent muscle necrosis. 
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SECTION I 
Some additional clinical, 
etiological and biochemical aspects 
of rhabdomyolysis 

CHAPTER 3-1 
Rhabdomyolysis and acute encephalopathy in 
an adult with late onset medium-chain acyl-CoA 
dehydrogenase deficiency 
P.J.E. Poels, W. Ruitenbeek, D.M. Turnbull, S. DiDonato, R.A. Chalmers 
and F.J.M. Gabreëls 
submitted for publication 
Summary 
A previously asymptomatic 30 year old man presented with rhabdomyolysis, 
muscle weakness and acute encephalopathy after strenuous exertion in the 
cold without adequate food intake. Serum and muscle carnitine were 
decreased. Urinary excretion of carnitine and glycine esters and biochemical 
examination of skeletal muscle and fibroblasts led to the diagnosis medium-
chain acyl-CoA dehydrogenase (MCAD) deficiency. A point mutation at nucle-
otide position 985 of the coding region of the MCAD gene was found. 
Carnitine substitution therapy improved the patient's condition, his exercise 
tolerance and his fasting features to a certain extent, but did not result in 
higher carnitine concentrations in muscle. 
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Introduction 
Rhabdomyolysis, acute muscle necrosis, can be due to a number of acquired 
or hereditary causes.1 The hereditary causes include specific defects of 
metabolism.2 The better known and extensively studied causes of hereditary 
rhabdomyolysis concern enzyme defects of glycogen metabolism and glycoly-
sis.3 In disorders of muscle lipid metabolism carnitine palmitoyltransferase 
(CPT) deficiency is the most common metabolic cause of rhabdomyolysis.3 No 
other abnormality of lipid metabolism has been identified as a major cause of 
rhabdomyolysis. In myopathic carnitine deficiency only three patients have 
been reported with recurrent attacks of rhabdomyolysis.4,5,6 Defects of fatty 
acid oxidation have rarely been associated with rhabdomyolysis: in one 
patient with long-chain acyl-CoA dehydrogenase deficiency, and in a child 
with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency.7,8 
Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency is the commonest 
of the disorders of fatty acid oxidation.9 As an inborn error of metabolism it 
has been recognized with increasing frequency in children with a Reye-like 
syndrome. As a consequence of the disturbance in the fatty acid oxidation, 
MCAD deficiency is associated with acute attacks of hypoketotic hypoglycemia 
and c6-c i 0 dicarboxylic aciduria.10 The attacks are provoked by stress, fever, 
viral illness and fasting." Between the attacks the patients feel well and only 
have mild proximal muscle weakness.12 Muscle and liver carnitine are abnor-
mally low, while serum carnitine fluctuates.9 In urine a characteristic profile 
of c6-c acylcarnitines can be demonstrated; especially octanoylcarnitine is 
always present and characteristic of MCAD deficiency, besides suberylglycine.12 
A deficient MCAD activity can be established in liver, muscle, peripheral 
mononuclear leukocytes and cultured fibroblasts," and is accompanied by a 
decreased oxidation rate of octanoic and myristic acid in cultured fibro-
blasts.14,15 Recently, DNA studies have identified a high prevalence of a point 
mutation at nucleotide position 985 of CDNA in MCAD-deficient patients.16 
The age of initial presentation of MCAD deficiency varies widely with some 
patients presenting acutely in early infancy with all the features resembling 
Rey's syndrome, while others present in childhood or as adults primarily with 
hypoglycemic episodes or muscular weakness. Duran et aL described an 
asymptomatic adult male with a decreased capacity for the oxidation of 
medium-chain fatty acids.17 
Here we describe the first patient with an initial clinical presentation of rhab-
domyolysis and acute encephalopathy, caused by MCAD deficiency at adult 
age, and associated with the point mutation in the DNA. 
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Case history 
A 30 year old male experienced progressive muscle weakness in arms and legs 
after one day of strenuous exercise in the cold without taking any food. He 
complained of headache, nausea, began vomiting and produced darkbrown 
coloured urine. At the end of the day he became lethargic, irritable and was 
admitted to the neurological department in a confused state. His medical his-
tory mentioned another episode of vomiting, headache and motor restlesness 
one year before, during a long motorbike trip without taking food. It was said 
that he sometimes had an aceton-like breath, especially when he had not 
taken a meal. The family history was non-contributory. 
On admission the patient was délirant. Blood pressure, pulse rate and temper-
ature were normal. Physical examination revealed general muscular weakness 
without atrophy. The liver was not enlarged. There was no focal neurological 
deficit. On admission ск level was 4,000 iu/1 (normal range 15-91) and myo­
globin 134 ng/1 (normak 85). The calcium level of 2.20 mmol/1 was low but 
within the normal range (2.20-2.60). Phosphate levels were increased to 1.70 
mmol/1 (normal range 0.76-1.24). Levels of transaminases were elevated, the 
γ-GT level normal. Potassium was increased to 5.8 mmol/1 (normal range 3.3-
4.4). The patient had a diminished production of urine: 500 cc per 24 hours. 
A transient increase of plasma urea to 26 mmol/1 (normal range 3.1-7.5) and 
creatinine to 193 |Jmol/l (normal range 70-106) indicated a moderate renal 
insufficiency. The urine contained protein and ketone bodies. 
Protein in cerebrospinal fluid was moderately increased to 530 mg/1 (normal 
value for age 150-450). Lactate was slightly increased to 1,690 Цто1/1 (normal 
range 1,200-1,600), the level of glucose was normal. Appropriate studies ruled 
out endocrinologie, immunologic and chronic infectious diseases, deficien­
cies of vitamines and disorders caused by toxic agents. 
Electroencephalography showed a generalized slowing background pattern, 
consistent with encephalopathy. During the acute phase a cerebral ст-scan 
showed very thin and slender side ventricles, indicative of cerebral edema. 
Electromyographic investigations revealed normal results. Electrocardiogra­
phy showed signs of left ventricle hypertrophy and repolarization distur­
bances. Two years later the results of EEG, cerebral ст-scan and ECG were nor­
mal. 
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Diagnostic investigations 
Clinical chemical aspects 
After the patient had made a complete recovery, biochemical study was per­
formed on the etiology of the rhabdomyolysis. The activities of carnitine pal­
mitoyltransferase ι and и in leukocytes were normal. Serial measurements of 
carnitine in serum showed a concentration of non-esterified carnitine in 
serum fluctuating between 6 and 38 |lmoles/l with a mean level of 21 |Jmolcs/l 
(in controls> 20 with a mean level of 38 |imoles/l)(TABLE I ) . 
Organic acids were determined in urine, using gas chromatography-mass 
spectrometry. Fast atom bombardment-mass spectrometry was used to ana­
lyze the excretion profile of acylcarnitines.18 The urinary samples showed a 
moderate dicarboxylic aciduria with increased excretion of suberylglycine and 
further increase on prolonged fasting. The acylcarnitine analysis showed the 
increased excretion of almost exclusively octanoylcarnitine. The identity of 
these acylcarnitines was confirmed by accurate mass measurements and by 
linked scanning of the isobutyl esters. 
Morphological studies 
A biopsy from the vastus medialis muscle was taken one month after the rhab-
domyolytic period. Only 20% of the fibers belonged to type I (normal 35-50). 
tobte L Serum and muscle carnitine concentrations. 
Serum and muscle carnitine concentrations before and during carnitine therapy 
in the patient and in controh. Values are expressed in \Lmoles/l and in mmoleslgr 
wet weight, respectively. 
without carnitine with carnitine controls 
serum 
total carnitine 
non-esterified 
range (mean) 
13-4З dj) 
6-38 (21) 
range (mean) 
25-78 (46) 
13-41 (26) 
> 2 5 
> 2 0 
muscle 
total carnitine 
non-esterified 
0.84 
0.73 
0.97 
0.61 
2.7-4.6 
2.2-4.2 
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FIGURE ι. Longitudinal section of the quadriceps muscle fibers, showing the pres­
ence of many lipid vacuoles between the myofibrils. Semi-thin toluidine 
blue stained Epon section; bar represents 1 pm. 
In semi-thin toluidine stained Epon sections an increased amount of lipid 
droplets was found between the myofibrils, mainly in type I fibers (FIGURE I ) . 
Electronmicroscopic study revealed local glycogen accumulation and numer­
ous lipid droplets. Morphometric stereological studies showed that the vol­
ume density of lipid droplets as percentage of the volume density of the myo­
fibrils was twice the control values: ц/ ^ in the patient was 0.87 ±0.15, and 
in controls 0.36 ± 0.07. 
Biochemical aspects 
Concentrations of total and non-esterified carnitine in muscle tissue, meas­
ured according to Parvin and Pande,1 9 were about 25% of control values 
(TABLE I ) . The activities of carnitine palmitoyltransferase 1 and 11 in muscle 
homogenate and the activities of citrate synthase, creatine kinase, cytochrome 
с oxidase, palmitoyl-CoA synthetase and succinate dehydrogenase were nor­
mal. 
The oxidation rates of radiolabelled palmitate, octanoate, butyrate and pyru-
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vate by intact cultured fibroblasts were determined according to Veerkamp et 
al.zo Only the rate of octanoate was diminished, being no more than 5% of 
the control mean: 0.11 versus 2.38 ±0.92 nmoles.hr"1.mg"1 protein, MCAD defi­
ciency was established in fibroblast homogenate: 1.6 versus 15.6 ± 6.2 mU.U" 
'citrate synthase, using an electron transfer flavoprotein-linked assay.11 The 
activity of short-chain and long-chain acyl-CoA dehydrogenases was quite 
normal. The MCAD activity was also measured in a 600 g supernatant of a fro­
zen skeletal muscle specimen, using phenazine methosulphate and dichlo-
rophenol indophenol as electron acceptor,22 but was hardly detectable. 
Molecular biological aspects 
Genomic DNA studies were performed on muscle tissue and skin fibroblasts. 
DNA was extractable from cultured skin fibroblasts and skeletal muscle 
homogenate and 2 |ig was used for PCR amplification. The oligonucleotide 
primers used create a restriction site for Ncoi in the mutant fragment.13 The 
PCR reaction was repeated for 30 cycles (1 minute denaturation at 94°C; 2 
minutes annealing at 50°C; and 2 minutes extension at jz°C; the final exten­
sion was for 7 minutes). The PCR-amplified 87-bp fragment was ethanol pre­
cipitated and resuspended in 20 μΐ of H2P. A 10 μΐ aliquot was digested with 
jU of Ncoi at 37°C for 2 hours. The original PCR fragment and the products 
of the restriction digest were electrophorized on a 3% agarose gel containing 
ethidium bromide. 
The patient was apparently homozygous for the 985 point mutation since all 
87 bp amplified DNA from both fibroblasts and muscle was digested with 
Ncoi to 61 en 26 bp fragments (FIGURE 2). 
Carnitine therapy 
The patient was treated with 8 gr DL-carnitine daily during 9 months. During 
the first month of carnitine supplementation the patient noticed an improve­
ment in his general condition. Total carnitine levels in serum became more 
constant and reached almost normal levels. The concentration of carnitine in 
muscle after 9 months of carnitine therapy had not increased (TABLE I) . There 
still was lipid accumulation between the myofibrils. 
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FIGURE 2. Electrophoretic pattern of the PCR fragments and of its products after 
Ncol digestion. 
Lane 1-6: control muscle 
Lane 7-8: present patients fibroblasts 
Lane 9-10: present patient's muscle 
Odd numbers: original PCR products 
Even numbers: digested PCR products 
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FIGURE 3. Concentrations of lactate, ketone bodies, free fatty acids, esterified and 
non-esterified carnitine during prolonged fasting. 
A. Without carnitine supplementation, 
в. During carnitine supplementation. 
Physiological tests 
Fasting studies 
Prolonged fasting studies were performed before and after the patient had 
been treated with carnitine for 40 days. The course of the most important 
metabolite concentrations in serum are shown in FIGURE 3. Both the concen­
tration of free fatty acids and ketone bodies increased during fasting, while 
the ratio ketone bodies/free fatty acids declined to 0.33 at 48 hours without 
carnitine supplementation. Glucose levels remained above 4.2 mmol/1 during 
48 hours, but declined at 55 hours to 3.0 mmol/1. A more pronounced keto-
genic response to fasting was observed during carnitine therapy, while the free 
fatty acid concentration did not raise abnormally. The ketone bodies/free 
fatty acids ratio now reached a value of 0.68 after a 48 hours fast. Glucose con­
centrations remained at 4.4 mmoles/1. 
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Exercise tests 
The patient participated in two prolonged exercise tests,24 one before and one 
during carnitine therapy. The patient became confused and experienced 
myalgia and nausea at the end of the exercise test without carnitine. Glucose 
level could no longer be maintained and lactate and ammonia rose markedly. 
During carnitine therapy he performed the prolonged exercise test with only 
slight myalgia and felt well after finishing. 
Discussion 
Since 1982 medium-chain acyl-CoA dehydrogenase deficiency has been rec-
ognized in young children with episodic illness resembling Reye syndrome, 
provoked by viral illness, fever and fasting.11'25,26,27 
The first episode is often before the age of two years." The patients show a 
broad spectrum of clinical presentation: intolerance to fasting, episodic vom-
iting, lethargy, altered consciousness and even coma. The outcome may be 
severe and fatal, but occasionally complete recovery may also occur.17 
Depending on the degree of involvement of liver, heart and skeletal muscle, 
the clinical features may range from recurrent episodes of hypoglycemia to 
progressive muscle weakness and myalgia. Serum creatine kinase may be 
moderately increased. In many patients the muscular symptoms are not 
prominent, but some have symptoms of muscle weakness. 
Diagnostic tests for MCAD deficiency are: 
1. measurement of free and esterified carnitine concentration in serum and 
muscle tissue. 
2. analysis of the profile of acylcarnitines excreted in urine, especially the 
amount of octanoylcarnitine, besides suberylglycine.18 
3. phenylpropionic acid loading test and determining the excretion of phe-
nylpropionic acid. 
Techniques such as gas chromatography-mass spectrometry and fast atom 
bombardment-mass spectrometry, make it possible to establish this metabolic 
disorder relatively easily. l8'28 Recently, MCAD deficiency has been associated 
with a molecular lesion involving an A-to-G nucleotide replacement at posi-
tion 985 of the MCAD CDNA.16 Though the prevalence of this mutation is high 
in MCAD deficiency patients,29 this approach is not yet appropriate to diag-
nose all patients with MCAD deficiency. 
Up till now only one asymptomatic adult with MCAD deficiency has been 
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described.17 We here report the first MCAD patient with a first clinical presen-
tation at adult age, whose medical history did not show any muscular prob-
lem during childhood and with a non-contributory family history. The 
clinical presentation of MCAD deficiency in this patient consisted of acute 
rhabdomyolysis and transient encephalopathy, provoked by prolonged 
exertion and fasting. 
Hithertoo, rhabdomyolysis has not been associated with MCAD deficiency. 
Rhabdomyolysis may be due to certain disturbed steps of the impaired beta-
oxidation of fatty acids in mitochondria. Fatty acids are important substrates 
for skeletal muscles, especially during prolonged exercise and fasting. The 
decreased oxidative capacity of muscles results in a moderate accumulation of 
lipid droplets in parallel rows between the myofibrils. 
The transient encephalopathy in the patient may be considered as a complica-
tion of rhabdomyolysis. However, rhabdomyolysis alone can not be the only 
causative factor, as muscle necrosis was moderate and serum creatine kinase 
not extremely elevated. The encephalopathy may also be partly ascribed to a 
diminished supply of ketone bodies to the brain. The brain depends upon 
glucose oxidation and during fasting mainly on ketone bodies. The oxidation 
of fatty acids themselves is not a good source of energy in the brain. When the 
excess of medium-chain fatty acids can no longer be metabolised by beta-oxi-
dation, as in MCAD deficiency, ketogenesis becomes impaired and omega-oxi-
dation takes place. Our patient had reached adulthood before he ever experi-
enced a prolonged fast, which was required to induce the symptoms. The 
impaired oxidation of octanoate may also have contributed to the develop-
ment of encephalopathic symptoms. Octanoate is known to inhibit the chor-
oid plexus excretory system for organic anions presumably via mitochondrial 
disruption. Inhibition of this transport system causes accumulation of octa-
noate in brain with expression of its encephalopathic effects.30 L-carnitine 
therapy may be useful for protecting the central nervous system through for-
mation of the non-toxic octanoylcarnitine having little effect on the transport 
system, and being excreted rapidly into urine. 
The main advice for patients with secondary carnitine deficiency is to avoid 
strenuous exercise and to take adequate meals at regular times." Carnitine 
supplementation in this patient actually worked with respect to exercise toler-
ance and protected against the metabolic consequences of prolonged fasting. 
It is remarkable, that in the present patient with the aberrant clinical symp-
toms the same point mutation has been found as in the far more severe cases 
of MCAD deficiency. The question arises by which factor(s) this clinical hetero-
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geneity is determined. Is the mutation at nucleotide position 985 causal in 
MCAD deficiency? Are other, still unknown, mutations responsible for this 
inborn error of metabolism, whether in an additive way or not? 
It has to be emphasized that also in adults with unexplained rhabdomyolysis 
and acute encephalopathy the diagnosis MCAD deficiency should be taken into 
account. 
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Rhabdomyolysis associated with simultaneous 
Epstein-Barr virus infection and isolation 
of echovirus 6 from muscle: a dual infection 
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Journal of Neurology, Neurosurgery and Psychiatry 1989; 52:512-513 

A DUAL INFECTION 
Introduction 
Acute rhabdomyolysis has been associated with a number of viral infec­
tions,1"10 which has been confirmed by a significant rise in serum antibodies 
or by isolation of virus from throatwashing, cerebrospinal fluid, urine or 
stool. Previous studies reveal that only influenza A and в, adenovirus type 2 
and Coxsackie-virus type А9 have been isolated from muscle tissue.2 We 
report a case of rhabdomyolysis associated with a dual viral infection. Epstein-
Barr virus (EBV) was identified serologically and echovirus 6 isolated from 
muscle. 
Case report 
A 17 year old boy was suffering from a flulike disease with headache, fever 
(4o0C), and progressive weakness of legs and arms. When after 3 days he 
started voiding dark coloured urine and when amoxicillin medication failed 
to lower his body temperature, he was admitted to hospital. His previous 
medical history was non-contributory. Previously he had been a healthy 
young man attending secondary school without exercise-related muscle com­
plaints and his family history gave no evidence of muscle disorders. 
On admission the rectal temperature was 39°C and the patient appeared 
mildly dehydrated. Blood pressure was 120/60 mm Hg and pulse rate 92 beats 
per minute. Some small axillary and inguinal lymphnodes were palpated. 
Liver and spleen were not enlarged. Thigh muscles were tender to palpation 
and weak against resistance. The patient was unable to stand alone without 
support. The result of the remainder of the physical examination was within 
normal limits. On admission an erythrocyte sedimentation rate of 3 mm/h 
was noted. White blood cell count was 9.1/mm', with 17% segmented forms, 
14% bands, 61% lymphocytes, of which many were atypically shaped, and 8% 
monocytes. Serum enzymes were strongly elevated: creatine kinase 54,050 iu/1 
(normal 15-91), ASAT 864 ш/1 (normal 7-25), ALAT 198 iu/1 (normal 5-25) and 
LDH 5,100 iu/1 (normal 155-275). γ-GT was normal. Urine analyses showed pro­
teinuria (2+) and many pigmented casts were detected. Immunoassay for 
myoglobin revealed a very high level in serum of 11,100 ng/ml (normal 0-85 
ng/ml) and presence in urine of 824,500 ng/ml. AST and ANF were normal and 
circulating immune complexes absent. The qualitative mononucleosis slide 
agglutination test was positive. By indirect immunofluorescence igM and igG 
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FIGURE. Biopsy from quadriceps muscle showing an unidentified NADH-positive 
structure with small round clear particles (bar = 50 pm). 
antibodies to EBV were detected at titres of 1:512 and 1:2,048 respectively. 
Complement fixation antibody titres to adenovirus, influenza virus, myco-
plasma pneumoniae, parainfluenza virus, measles and herpes simplex virus 
were negative. 
The patient was immediately treated with infusion therapy of 4I NaCl 0.9% 
per 24 hours and forced diuresis in order to prevent acute renal insufficiency 
as consequence of myoglobinuria. Urine was kept alkaline by N a H C O 1.5% 
infusion. No signs of renal failure developed. On the 8th day of admission a 
maculopapulous rash developed, which is very characteristic of a hypersensi-
tive reaction to penicillin in infectious mononucleosis patients. The muscle 
weakness gradually disappeared within 2 weeks and full recovery took place. 
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Special studies 
On the 9th day after admission a needle biopsy of the quadriceps muscle was 
carried out. The structure of muscle fascicles was well preserved. Necrosis was 
absent; some mononuclear cell infiltration could be still noticed. One baso­
philic fibre was seen; one fibre showed an unidentified NADH-positive struc­
ture filled with small round clear particles (FIGURE). Electronmicroscopically 
z-band streaming and some cytoplasmic bodies were seen. No viral inclusions 
could be detected. 
For virus isolation cultures of primary monkey kidney cells, of human diploid 
fibroblasts and of Hep-2 cells were inoculated with patient's material by stan­
dard procedures." Inoculated cultures were examined for the development of 
a cytopathogenic effect for a period of 3 weeks. Isolated viruses were typed 
with the use of type specific neutralising antisera. The isolate was identified as 
echovirus 6. 
Discussion 
The diagnosis rhabdomyolysis was established at admission, because of ten­
derness and weakness in both legs, myalgia, darkbrown coloured urine and 
strongly elevated levels of myoglobin and ск in serum. Adequate therapy'3 
possibly prevented the developement of renal insufficiency, a wellknown 
complication of rhabdomyolysis. Infectious mononucleosis was suspected 
because of fever, lymphadenopathy, atypical lymphocytosis and the character­
istic skin rash as a reaction to amoxicillin. An EBV infection was serologically 
confirmed. 
It is not always possible to make a clear distinction between postinfectious 
("toxic") rhabdomyolysis and true viral myositis. These diagnostic terms are 
used synonymously in most case reports about rhabdomyolysis related to viral 
infection. This probably illustrates the existence of a wide spectrum of mus­
cle pathology extending from a toxic muscle fibre necrosis following febrile 
disease, to acute inflammatory myositis with rabdomyolysis due to viral infes­
tation. It would be better, however, to limit the diagnosis viral myositis to 
those cases in which inflammatory changes in muscle are present and/or virus 
has been isolated from muscle. Postinfectious rhabdomyolysis is often procee­
ded by upper respiratory infections, especially in children, and in some cases a 
positive family history is noted. 
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In the present case it is clear, however, that this previously healthy young man 
suffered from a true acute viral myositis with mild rhabdomyolysis. Echovirus 
6 was isolated from muscle and thought to be the causative agent of rhabdo-
myolysis. Still the question remains whether any relation exists between echo-
virus 6 infection and EBV. The contribution of EBV to the pathogenesis of the 
attack of rhabdomyolysis is unclear. In the literature rhabdomyolysis has been 
reported to be associated with EBV in four patients in whom the infection was 
serologically confirmed and rhabdomyolysis was evident from weakness, ele-
vated CK and renal insufficiency.7,9,14,15 Only in the patient reported by Schle-
singer et al. was a muscle biopsy carried out, which showed no inflammatory 
changes.7 To our kwowledge EBV has never been detected in muscle and any 
direct causal relationship between mononucleosis and rhabdomyolysis has 
not yet been documented. In the three patients of Schlesinger et al, Kantor et 
al, and Friedman and Libby a postinfectious toxic factor may have played a 
role in the development of rhabdomyolysis.7,9'14 Also in our patient a direct 
effect of EBV on muscle seems unlikely. One might hypothesize that EBV has 
altered the patient's immune system and made him more susceptible to the 
effects of echovirus infection, EBV infection might have made it possible for 
echovirus 6 to invade directly into muscle tissue and thus to trigger rhabdo-
myolysis. The same mechanism may have played a part in the dual infection 
with streptococcus and Picornavirus in the case reported by Porter et al* Also 
Fukuyama et al. describe a patient in whom Coxsackie virus infection was 
determined by serology and picornavirus-like crystals were found in muscle.4 
These infections might have interacted synergetically. 
Our knowledge about this type of muscle disorder could be augmented by 
carrying out more frequently histological studies together with isolation of 
virus in case of postinfectious rhabdomyolysis. A needle biopsy, as in our case, 
suffices. 
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CHAPTER 3.3 
Rhabdomyolysis associated with malaria 
tertiana in a patient with myodenylate 
deaminase deficiency 
P.J.E. Poels, W.M.V. Dolmans and F.J.M. Gabreëls 
Tropical and Geographical Medicine 1993; 45:645-647 
Summary 
A male patient presented with malaria tertiana due to Plasmodium vivax. He 
developed a severe attack of rhabdomyolysis with acute renal failure. The 
patient was treated succesfully with chloroquine medication. After complete 
recovery further muscle study revealed a deficiency of myoadenyl deaminase 
(MAD). The infection with Plasmodium vivax problably has been the trigger-
ing factor in the process of muscle necrosis, because the patient also had MAD 
deficiency. 
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Introduction 
Malaria is an import disease with a rapidly increasing incidence in the West 
European countries. In The Netherlands 277 new cases have been reported in 
1991, mainly consisting of Plasmodium falciparum infection.1 Malaria tropica 
due to Plasmodium falciparum is the severe form, while malaria tertiana and 
quartiana have a rather benign course and usually no severe complications.2 
However, in the patient here described, the course of the illness took an unex­
pected turn. The patient suffered from malaria tertiana due to Plasmodium 
vivax and was treated succesfully. Yet during recovery he developed a severe 
attack of rhabdomyolysis with acute renal insufficiency and cardiomyopathy. 
Further examination including muscle biopsy was performed to explain the 
development of muscle necrosis. 
So far as we know rhabdomyolysis has not previously been associated with 
malaria tertiana. The possible causes of rhabdomyolysis in this patient are dis­
cussed. 
Case report 
A 32 year old male was referred to the tropical diseases clinic with general mal­
aise, night sweats and fever. He had been working as a civil engineer for two 
years in the Far East. Before departure he had received all vaccinations needed. 
In Indonesia he had taken as malaria prophylaxis proguanil hydrochloride 100 
mg daily and chloroquine 300 mg base weekly, sulfadoxine-pyrimethamine 
and chloroquine sulphate, and later chloroquine sulphate only. Two months 
before returning home he had stopped all medication. One week prior to his 
return to the Netherlands, he walked the mountains and experienced a 
diminished exercise-tolerance. He complained about nausea and developed 
irregular low grade fevers. He had never had any exercise-related muscle prob­
lems. The family history was non contributory. 
On admission he felt sick, without vomiting. He did not complain about 
myalgia. There were no cardiac nor pulmonary symptoms. Micturition was 
undisturbed. Physical examination revealed a weak and ill patient with a 
raised body temperature of з8,4°С. He had postural hypotension: in supine 
position his blood pressure was 105/50 mm Hg and the pulse rate 80/min, but 
on standing up he collapsed. The spleen was just palpable. 
Standard hematologic investigations, renal and thyroid functions, and serum 
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FIGURE ι. Right arm of the patient showing the swollen skeletal muscles during the 
attack of rhabdomyolysis (A) and 4 weeks after recovery (в). 
protein were normal. Serum creatine kinase (ск) activity was 70 iu/1 (normal 
range 15-91), ASAT 33 iu/1 (normak 25), ALAT 48 iu/1 (normak 30) and LDH 457 
iu/1 (normak 275). In the urine protein was positive, sedimentation showed 
0-2 erythrocytes, 0-2 leukocytes and hyalin casts. 
The combination of fever, headache, splenomegaly and inadequate use of 
malaria prophylaxis with a history of recent travel in a malaria endemic area 
was suggestive of malaria. The first day of admission the diagnosis was con­
firmed by identification of Plasmodium vivax in the red blood cells. The 
patient was treated with chloroquine sulphate (1,500 mg base total in 3 days), 
after which the fever disappeared and repeated blood examinations for malari­
aparasites were negative. 
The second day of admission the patient's blood pressure decreased to 70/50 
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mm Hg and he developed oliguria, dyspnoea, tachypnoea of 40/min and 
metabolic acidosis. He was transferred to the intensive care unit. Skeletal 
muscles of both arms were grossly swollen (FIGURE IA). Muscle power was 
reduced and extension of the fingers was painful. Subsequently the muscles of 
the lower extremities became weak, swollen and tender. The patient produced 
dark coloured urine, containing myoglobin in a concentration higher than 
30,000 ng/ml (normally absent). 
The diagnosis rhabdomyolysis was confirmed by increased ск level up to 
85,500 iu/1 (normal range 15-91). Transaminases were elevated: LDH 4,228 iu/1, 
ASAT 10,052 iu/1 and ALAT 446 iu/1. A needle biopsy taken in the acute phase of 
the rhabdomyolysis showed extensive muscle necrosis. No virus could be iso­
lated from muscle. 
The urine production had diminished; the levels of ureum had increased to 
20.9 mmol/1 (normal range 4-7) and of kreatinine to 250 (Jmol/l (normal 
range 60-105). Because of acute renal failure the patient received one treat­
ment with hemodialysis and was treated with mannitol infusions. Cardio­
myopathy was suspected because of low voltage potentials on electrocardio­
graphy and this was confirmed by echocardiography. Because of respiratory 
failure ventilatory assistance was needed for 10 days. 
The levels of serum CK and transaminases were determined daily and gradual­
ly declined to normal. It took 4 weeks before the patient made a complete 
recovery. The strength of skeletal muscles increased and the exercise-tolerance 
gradually improved. After 4 weeks the patient's arms and legs had their nor­
mal appearance again (FIGURE IB). Repeated cardiological examination was 
normal. 
Special studies 
Further studies were performed in order to detect the etiology of the severe 
attack of rhabdomyolysis. 
The concentrations of free and esterified carnitine in serum and the activity of 
carnitine palmitoyltransferase in leukocytes were normal. Hemoglobin elec­
trophoresis showed no HbS. There was no glucose-6-phosphate dehydroge­
nase deficiency in erythrocytes. The enzyme activity of acid mal tase in leuko­
cytes was normal. A standardized ischemic exercise test was performed.3 This 
showed a normal rise of venous lactate, but the rise of ammonia was absent. 
A muscle biopsy of the m.quadriceps was performed 4 weeks after the attack 
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FIGURE 2. Muscle biopsy of the patient with negative staining for myoadenylate (A). 
For comparison a positive staining in a control (в). 
of rhabdomyolysis for further examination. Muscle homogenate was pro­
cessed according to standard procedures for histological, histochemical and 
biochemical studies. Histological examination of the muscle biopsy revealed a 
decreased number of type 1 fibers of 21% (normal range 35-50). Sudan Black 
staining showed an increased amount of lipid droplets. Myophosphorylase 
and PAS staining were normal. The staining for myoadenyldeaminase was 
negative (FIGURE 2A). Biochemical studies of the muscle homogenate showed 
normal oxidation of pyruvate and malate and a normal production of ATP. 
Discussion 
The patient presented with malaria tertiana due to Plasmodium vivax fol­
lowed by a severe attack of rhabdomyolysis. Unlike malaria tropica due to 
Plasmodium falciparum, malaria tertiana usually has a benign course.2 How-
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ever, in this patient the disease had a life-threatening course due to severe 
rhabdomyolysis, complicated by transient cardiomyopathy, acute renal failure 
requiring hemodialysis and respiratory failure necessitating ventilatory assis-
tance. 
While malaria tertiana is not a rare disease in tropical countries, it has never 
been been associated with rhabdomyolysis. Only two reports have been pub-
lished about rhabdomyolysis in severe cases of falciparum malaria.4,5 In one of 
these reports the patient was treated with chloroquine.4 Chloroquinc and 
hydroxychloroquine are well-known antimalaria agents. They are also exten-
sively used in the long-term treatment of collagen vascular and dermatologie 
disorders. Six cases of toxic myopathy and/or neuropathy have been described 
after long-term administration of chloroquine.6 A slowly progressive muscul-
ar weakness occurred after intake of chloroquine or hydroxychloroquine over 
several years. The myopathy consisted of type 2 fiber atrophy and a specific 
ultrastructural pattern of accumulated myeloid bodies, glycogen and curvilin-
ear bodies. The level of serum CK in these patients was only mildly elevated. 
To our knowledge an association of the use of chloroquine with acute rhabdo-
myolysis has never been described. Our patient had stopped all medication 
one month before his admission and was treated with chloroquine during 
three days only. He did not present with slowly progressive muscle weakness, 
but developed a fulminant attack of rhabdomyolysis with strongly elevated 
serum CK levels. 
The ischemic exercise test in this patient was suggestive of a deficiency of 
myoadenylate deaminase (MAD). This enzyme defect was confirmed by histo-
enzymatic stain for MAD in muscle biopsy. Myoadenyl deaminase is involved 
in purine nucleotide breakdown by catalyzing the irreversible deamination of 
AMP into IMP, while ammonia is being formed.7 This reaction chain is active 
during muscle activity, especially during ischemic exercise. Usually, in MAD 
deficiency there is no characteristic set of clinical signs or symptoms and the 
pathogenetic significance of MAD deficiency remains still controversial.8 Gen-
erally, MAD deficiency has little serious consequences and many patients are 
non-symptomatic.8 
MAD deficiency has frequently been associated with several well classified 
neuromuscular diseases, such as acid maltase deficiency.8 It has only rarely 
been associated with rhabdomyolysis. Tonin et al. evaluated 77 cases of rhab-
domyolysis and found in 3 of them a MAD deficiency.9 
The question arises whether MAD deficiency in this patient is merely coinci-
dental or plays a causative role in the development of rhabdomyolysis. The 
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previous medical history of the patient did not mention any muscular prob-
lems, except once during strenuous exercise one week before admission. 
In this patient the clinical picture was dominated by the infection with the 
protozoan Plasmodium vivax, treated succesfully by chloroquine. The MAD 
deficiency may be considered as a co-factor in the development of the clinical 
features of rhabdomyolysis. Immune and toxic mechanisms, especially the use 
of chloroquine, however, cannot be excluded as causative factors. Also fever as 
such - in combination with MAD deficiency - may have played a role in the 
process of muscle necrosis. 
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Exertional rhabdomyolysis in a patient with 
calcium adenosine triphosphatase deficiency 
P.J.E. Poels, R.A. Wevers, J.P. Braakhekke, A.A.G.M. Benders, J.H. Veerkamp 
and E.M.G. Joosten 
Journal of Neurology, Neurosurgery and Psychiatry (in press) 
Summary 
A patient with exertional rhabdomyolysis and continuously elevated serum 
creatine kinase was investigated. The known causes of recurrent attacks of 
rhabdomyolysis were ruled out by appropriate histochemical and biochemical 
investigations. During ischemic exercise tests an abnormal rC-efflux from 
exercising muscles was observed. The patient was found to have a deficiency 
of muscular Ca2+-ATPase. Dantrolene sodium therapy gave relief of muscle 
symptoms and improved the exercise tolerance. Both the ск level and the K+-
efflux in ischemic forearm testing became normal on this therapy. 
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introduction 
Recurrent attacks of exertional rhabdomyolysis can develop from several 
enzyme defects of glyco(geno)lysis or lipid metabolism.1 Rhabdomyolysis has 
never been associated with Ca2+-adenosine triphosphatase (Ca2+-ATPase) defi­
ciency. This rare disorder of muscle function was first described by Brody in 
1969.2 In recent years three reports have been published, describing patients 
with deficiency of sarcoplasmic reticulum (sR)Ca2+-ATPase.3'4'5 Exercise-
induced muscle contractures and impaired relaxation of exercising muscles 
belong to the main clinical symptoms. The deficiency causes a reduced uptake 
of Ca2+ in sarcoplasmic reticulum. Several studies have shown the importance 
of calcium ions in the contraction-relaxation cycle of striated muscles.2 
We describe a patient with exertional myalgia and recurrent rhabdomyolysis. 
We tested this patient with dantrolene sodium since this drug has been sug­
gested to be useful in the treatment of exertional myalgia and recurrent rhab­
domyolysis.6'7,8 Dantrolene sodium acts primarily by decreasing SR calcium 
release and depresses the trigger mechanism for the excitation-contraction 
coupling, which is supposed to play a key role in the development of muscle 
pain and stiffness.6'9 The effect of dantrolene sodium on muscle symptoms 
and on ischemic exercise tests is discussed. 
Case report 
A 38 year old male presented with exertional myalgia and postexercise muscle 
weakness. These symptoms of exercise-intolerance started during the first 
decade of life. His skeletal muscles became stiff and painful already 5 minutes 
after the start of moderate isometric exercise. He had many episodes of pig-
menturia, especially after sporting. He was not able to play a volleyball match 
to the end because of stiffening in the exercised muscles. The muscle symp­
toms then lasted for at least 12 hours. He frequently experienced "cramping" 
in the calf muscles. Walking and cycling at peace caused no muscle problems. 
When chewing firmly, the masticatory muscles became stiff and the relaxa­
tion was impaired. The patient did not experience a second wind phenome­
non. The family history was non-contributory. Physical examination revealed 
no abnormalities. There was no muscle atrophy and no muscle weakness. 
Grip and percussion myotonia were absent. Laboratory studies showed a con­
tinuously elevated serum ск ranging from 500 to 1,500 iu/1 (normal range 15-
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91). After sport, serum ск rose to 11,000 iu/1. A normal biochemical and 
hematological profile was obtained. Blood lactate level was within the normal 
range and showed a fourfold rise in response to exercise. Electromyography 
showed normal conduction velocities. No myotonic discharges were observed 
in intrinsic hand muscles, quadriceps or tibialis anterior muscle. 
Because of recurrent attacks of exertional myalgia the patient was treated with 
dantrolene sodium. The dose was slowly built up to 150 mg a day and contin­
ued for 6 months. Exercise-tolerance improved and the patient was able again 
to participate in sport without muscle problems. When dantrolene sodium 
was discontinued for two months, all muscle complaints returned. Symptoms 
disappeared again when the medication was resumed. In the period without 
dantrolene sodium, ск level was determined twice and clearly elevated to 1,125 
and 1,429 iu/1 respectively. During dantrolene sodium treatment ск level was 
determined 3 times and had decreased to 105,185, and 115 iu/1 respectively. 
Special studies 
A muscle biopsy from the vastus medialis was processed according to standard 
procedures for histochemistry and electron microscopy. Carnitine palmitoyl­
transferase 1 and 11 activities were measured in leukocytes and in muscle 
homogenate with the exchange assay.10 The activity of alpha-glucosidase was 
determined in leukocytes and in muscle. Concentrations of free and esterified 
carnitine were determined in blood and muscle tissue." An extensive bio­
chemical study of mitochondrial metabolism and enzymes was performed 
according to standard procedures.11 
In muscle homogenates (i% w/v) the Ca2+-dependent Mg2+-ATPase of SR was 
investigated by measurement of the Caz+-dependent 3-0-methylfluorescein 
phosphatase (3-0-MFPase) activity according to the method described by 
Everts et al.li The Na+/K+-ATPase activity was estimated from the ^-depen­
dent 3-0-MFPase activity according to Norgaard et al.4 
In order to exclude a glyco(geno)lytic enzyme defect glycolytic enzymes in 
erythrocytes were determined and ischemic forearm tests were carried out 
under standardized conditions.15 Two ischemic forearm tests were performed 
during dantrolene therapy and two tests without medication. In the blood 
samples taken before and immediately after exercise, changes in plasma elec­
trolyte levels were studied.16 
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Results 
Laboratory investigations 
Normal values were found for carnitine palmitoyltransferase ι and и in leuko­
cytes and in muscle homogenate. In red blood cells there was no deficiency of 
glycolytic enzymes. The activity of alpha-glucosidase in leukocytes and in 
muscle was normal. Free and esterified carnitine in serum and muscle were 
normal. Muscle homogenate showed a normal oxidation rate of [i-I4C] pyru­
vate and [U-I4C] malate, no defect in ATP metabolism and normal activities of 
mitochondrial enzymes. 
The Ca2+-dependent 3-0-MFPase activity in muscle was significantly reduced 
to 589 pmol/min per mg protein compared to the control value of 1,134 — 2 2 7 
(n=i4). A normal activity was found for K+-dependent 3-0-MFPase of 414 
pmol/min per mg protein versus 382 ± 73 in controls (n=i4). 
Morphological studies 
Histologic studies of the muscle biopsy showed 19% central nuclei (normak 
3%), some necrotic fibres and an increased variation of fibre diameter. Myo-
phosphorylase and myoadenylate deaminase staining reactions were positive. 
A trichrome stain was negative and no ragged red fibres were seen. Histo-
chemical study revealed a slight amount of subsarcolemmal PAS-positive 
material. Electron microscopy showed muscle fibers with an increased amount 
of glycogen. A substantial number of subsarcolemmal mitochondria were 
swollen and contained crystals (FIGURE I ) . The structures of the triad and the 
tubular elements of sarcoplasmic reticulum were normal. 
Ischemic forearm tests 
All four ischemic exercise tests showed a normal rise of venous lactate and 
ammonia. During the two forearm tests without medication an excessive 
increase of serum potassium was found immediately after ischemic exercise 
(FIGURE 2). The K+-efflux was normal in the two ischemic forearm tests at 
dantrolene sodium treatment. 
Discussion 
Ca2+-ATPase deficiency is a rare inborn error of metabolism. Its clinical pres­
entation is not specific. Impaired muscle relaxation, muscle contractures and 
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FIGURE ι. Electron microscopy. A number of subsarcolemmal mitochondria which 
are swollen and contain crystalline inclusions. Bar = 1 \lm. 
exertional muscle pain are the main features. Hitherto rhabdomyolysis has 
not been associated with Ca2+-ATPase deficiency. The diagnosis is established 
by measuring the microsomal Ca 2 + -uptake, 2 ' 4 quantifying the activity of 
Ca2+-ATPase in muscle homogenate 1 4 or by immunochemical tests.4 
K+-efflux from exercising muscle is considered a normal physiological phe­
nomenon. '
6
 The efflux of K+ in the venous return blood of the exercising 
forearm was excessive in this patient. The normal values found for Na+/K+-
ATPase activity excluded a re-uptake disorder of K+ as cause of its excessive 
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FIGURE 2. Abnormal increase of serum potassium in relation to the concentration 
lactate during the ischaemic forearm test. During dantrolene sodium 
(DaNa) medication the K+-release was in the normal range of the con­
trols. 
efflux. T h e K+-efflux may be explained by the effect of a disturbed Ca 2 + -
homeostasis on the Ca2 +-activated K+-channels.1 0 This hypothesis is sup­
ported by the strongly reduced activity of sarcoplasmic reticulum Ca2+-ATPase 
that was found in the muscle homogenate of this patient. 
Electron microscopic findings showed normal structures of triad and tubular 
elements of sarcoplasmic reticulum, but swollen mitochondria with crystals. 
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Crystalline mitochondrial inclusions are often seen under pathological condi­
tions concerned with energy metabolism. These crystals may be considered as 
a secondary effect of the disturbed calcium homeostasis of mitochondria. 
Up till now four case reports of Ca2+-ATPase deficiency have been published. 
The first case described by Brody in 1969 had marked problems with relaxa­
tion of exercising muscles.2 Karpati et al. described 4 male patients with simi­
lar complaints about exertional muscle stiffness and contractures, ск level in 
only one of them was slightly elevated. The mode of inheritance in this fami­
ly was autosomal recessive.4 Danon et al. described 4 family members with 
impaired muscle relaxation and an autosomal dominant mode of inheri­
tance.3 Taylor et al. reported a Ca2+-ATPase deficiency in a patient with an 
exertional muscle pain syndrome.5 Our patient suffered from exercise-
induced myalgia, recurrent attacks of rhabdomyolysis with pigmenturia and a 
constantly elevated CK level. Relaxation of muscles was sometimes difficult 
but not the patient's main problem. 
The clinical picture of muscle relaxation problems in these patients resembles 
myotonic dystrophy or myotonia congenita. However, these patients do not 
demonstrate clinical or electrical myotonia. Their delayed muscle relaxation is 
painless in contrast to muscle contractions in myotonia syndromes. On the 
other hand, Ca2+-ATPase deficiency shows a resemblance with McArdle's dis­
ease and phosphofructokinase deficiency because of the electromyographical 
silence during relaxation. 
The main difference between our patient and the previous cases,2'3'4'5 is the 
exertional recurrent rhabdomyolysis, confirmed by elevated ск levels. For 
muscle relaxation to occur, Ca2+-ions released into cytosol during contrac­
tion, must be taken up into the SR lumen through activity of Ca2+-ATPase 
located in the SR membrane. The partial deficiency of this enzyme may 
explain the main presenting symptoms in this disease: problems in relaxation 
of muscles, aggravated by exercise, muscle stiffness and exertional myalgia. 
When sarcoplasmic reticulum Ca2+-uptake cannot keep pace with Ca2+-
release, then an accumulation of Ca2 + in muscle cytosol will occur. If at a crit­
ical level, a sustained elevation in cytosolic Ca2+-concentration will be damag­
ing to muscle cells. Muscle cell necrosis and pigmenturia will be the conse­
quence. Myoglobinuria has not yet been associated with Ca2+-ATPase deficien­
cy, which may be attributed to the very small number of case reports up till 
now. The degree of deficiency of Ca2+-ATPase may be important for the devel­
opment of muscle damage. Verapamil and dantrolene sodium are the thera­
peutic drugs that have been successfully used in the treatment of exertional 
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myalgia. In the patient described by Taylor et al. dantrolene sodium reduced 
the pain, but produced unacceptable weakness.5 Verapamil proved to be effec­
tive. The therapeutic use of dantrolene sodium in preventing muscle necrosis 
has been reported before in animal experiments.6 Its beneficial effect in 
humans has also been reported by us and others in treating exertional myalgia 
and preventing recurrent attacks of rhabdomyolysis.8,9,17 In our patient 
dantrolene sodium also had a positive effect upon exercise tolerance and 
muscle complaints; moreover ск level and plasma potassium efflux from 
ischemic exercising muscles became normal. 
Recurrent rhabdomyolysis in metabolic myopathies is mainly precipitated by 
exercise. The number of recognized metabolic defects has increased in the 
past two decades, but in about half of the cases the biochemical cause of 
recurrent rhabdomyolysis remains unknown.1 We plead for taking into 
account Ca1+-ATPase deficiency as a metabolic cause of recurrent exertional 
rhabdomyolysis. 
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CHAPTER 4 . 1 . 
In vitro contraction test for malignant 
hyperthermia in patients with unexplained 
recurrent rhabdomyolysis 
P.J.E. Poels, E.M.G. Joosten, R.C.A. Sengers, A.M. Stadhouders, 
J.H. Veerkamp and A.A.G.M. Benders 
Journal of the Neurological Sciences 1991; 105:67-72 
Summary 
A few cases of non-anesthetic-induced rhabdomyolysis in humans, predis­
posed to malignant hyperthermia (мн), have been described in literature. We 
studied a group of 6 consecutive patients with unexplained and recurrent 
attacks of rhabdomyolysis with the test used to determine susceptibility to 
мн, the in vitro contraction test (IVCT). The results of the г ст showed 5 of 
these 6 patients to be мн-susceptible. In cultured muscle cells from one of 
these patients a disturbed calcium homeostasis could be demonstrated. The 
relation between мн and recurrent rhabdomyolysis is discussed. 
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Introduction 
Recent studies have demonstrated that in about half of the patients with 
recurrent rhabdomyolysis systematic investigation of a.o. glyco(geno)lysis and 
carnitine palmitoyltransferase (CPT) activity will disclose specific enzymopa­
thies.1 The rest may have hitherto undiscovered metabolic diseases or genetic 
defects of the sarcolemma. Malignant hyperthermia (мн) can be suspected to 
be one of the causes of recurrent rhabdomyolysis.* The clinical pathophysio­
logy of мн is generally triggered by commonly-used anesthetic agents and 
manifests as a fulminating hypermetabolic crisis characterized by high body 
temperature, metabolic and respiratory acidosis, skeletal muscle rigidity and 
rhabdomyolysis.3 However, many people carrying the мн trait, as determined 
in familial studies, do not readily develop мн crises, even when exposed to 
мн triggering agents.4 Several attacks of rhabdomyolysis not caused by 
anesthetics have been described in мн-susceptible patients.2'5,6'7'8 
It was our aim to determine whether any connection existed between MH-SUS-
ceptibility and recurrent rhabdomyolysis in a patient from a family wherein 
unexplained rhabdomyolysis was inherited as an autosomal dominant trait. 
To do this we subjected a muscle biopsy specimen from this patient to the test 
that is generally used to determine susceptibility to мп, the in vitro contrac­
tion test (г ст). In addition, since a breakdown in the mechanism regulating 
calcium ion influx into the myoplasm is believed to underly both мн and 
rhabdomyolysis, calcium homeostasis was studied in cultured muscle cells 
from this patient. 
Subsequently, we added five consecutive patients with unexplained recurrent 
rhabdomyolysis to this study with г ст. 
We report here the results of IVCT in these 6 patients and discuss the relation 
between recurrent rhabdomyolysis, мн-susceptibility and calcium homeosta­
sis. 
Case histories 
Patient ι is a 32-year-old male who since early childhood experienced many 
disabling attacks of rhabdomyolysis, always following trivial viral infections 
with fever. He has been admitted to the hospital several times for fever fol­
lowed by painful contractures, muscle weakness and the production of dark 
urine. 
Scrum creatine kinase (ск) activities and myoglobin concentrations reached a 
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FIGURE i. Pedigree of the family of patient 1 shows the persons who are affected by 
attacks of rhabdomyolysis. The numbers below the box or circle refer to 
interictal CK values at rest, on one occasion determined in all these family 
members (normal 15-91 iu/1). 
level of 89,500 iu/1 (normal 15-91) and 18,000 ng/ml (normak 80) respective­
ly during one of these attacks. After each attack the patient made a good 
recovery. In his childhood he was only once admitted for surgery and had an 
uneventful anesthesia. 
The family consists of nonconsanguineous parents and nine children. Several 
times we examined his father and brother, who also suffered from severe 
attacks of rhabdomyolysis following flu-like diseases. During one attack of 
rhabdomyolysis his brother had to be admitted because of cardiac arrest to the 
cardiac care unit, where he developed acute renal insufficiency for which 
hemodialysis was required. His father also required hemodialysis because of 
acute renal insufficiency during a severe attack of rhabdomyolysis. Two other 
brothers had experienced periods of muscle pain and the production of dark 
urine following fever; the eldest son at least 6 times, the second son only once. 
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Serum ск activities were determined in both his parents and sibs and were ele­
vated in four of them. The pedigree and the corresponding resting serum ск 
values for the family members are presented in FIGURE I. 
Patient 2 is a 39-year-old male who experienced 3 attacks of rhabdomyolysis 
with pigmenturia, painful thigh contractures, swollen muscles and muscle 
weakness. The first attack occurred several hours after general anesthesia, the 
second 4 days after spinal anesthesia and the third attack during an episode of 
bedrest because of brain concussion. His son had experienced hyperpyrexia 
and thigh muscle contractures during anesthesia for tonsillectomy. His mother 
had suffered from muscle pain and stiffness in all limbs after anesthesia for 
teeth extraction. His sister had had a temporary muscle weakness of one leg 
after gynecological surgery. 
Patient 3 is a 26-year-old male who suffered from recurrent attacks of non-
anesthetic-induced rhabdomyolysis from childhood onwards. His case histo­
ry was described earlier.9 As a child he was easily fatigued and he had episodes 
of malaise, muscle weakness and pigmenturia once or twice a year. During 
one of these attacks serum ск activities were elevated to 10,584 iu/1 (normal 
15-91). From adolescence onwards the attacks were not only triggered by exer­
tion, but also by emotion and stress. His family history was non contributory. 
Patient 4 is a 20-year-old male who suffered from several attacks of rhabdo­
myolysis and pigmenturia at the start of physical training or following long-
lasting exercise as amateur cyclist, and also during episodes of emotional 
stress. Serum ск activities during one of these attacks were 14,230 iu/1. The 
patient experienced swollen, painful thighs and proximal muscle weakness. It 
took him several days to recover. His father is also an amateur cyclist and has 
never experienced any muscular symptoms. 
Patient 5 is a 19-year-old male who suffered from two separate attacks of severe 
myalgia, rhabdomyolysis and pigmenturia, each after longlasting and heavy 
exertion. Serum ск activities were elevated to 92,000 iu/1. Physical examina­
tion shortly after one attack showed weakness in muscles of both arms and 
legs. Serum ск activities between the attacks remained slightly elevated, 194 
iu/1. 
Patient 6 is a 51-year-old male with a severe attack of rhabdomyolysis followed 
by renal insufficiency. Serum ск during that attack was 100,000 iu/1. No 
cause for this attack has been discovered. The patient made a good recovery. 
He still complains about muscle pain in both legs during exercise. He has 
never experienced muscle weakness. Another time, during moderate exertion, 
he fell on the ground and lost his consciousness. Since the patient and two of 
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Most relevant data of investigation in the 6patients as presented in the text. 
Patient no. 1 2 3 4 5 6 
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his sibs suffer from epilepsia, this was interpreted as an epileptic insult. Serum 
CK activities a few days later were elevated to 3,300 iu/1. Serum ск activities, 
determined several times outside these events, were between 100 and 500 iu/1. 
The family history for muscular disorders was negative. 
Routine laboratory blood and urine examination in patients 1-6 revealed no 
abnormalities, except the elevated serum ск activities in the patients 1, 2, 5 
and 6 as presented in TABLE I. 
Methods and materials 
All patients performed an ischemic forearm test under standardized condi­
tions.10 In the blood sample of patient 1, taken immediately after exercise, 
changes in plasma electrolyte levels upon ischemic forearm exercise were stud­
ied.11 The activities of carnitine palmitoyltransferase 1 and 11 were measured in 
leukocytes applying the exchange assay.12 Skeletal muscle biopsies were taken 
from the m.vastus medialis under regional anesthesia using an amide local 
anesthetic.13 The activities of carnitine palmitoyltransferase 1 and 11 were 
measured in muscle homogenate; free and esterified carnitine were deter­
mined in both serum and muscle,14 and an extensive biochemical study of 
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mitochondrial metabolism was performed.15 Muscle samples removed for the 
in vitro contraction test were immediately transferred to the laboratory in a 
Krebs-Ringer solution. The muscle fascicle was fixed at one end and the other 
end was attached to a force displacement transducer, Schaevitz FrD-G-io. The 
muscle fascicle was directly stimulated supramaximally and equilibrated. 
Thereafter the test was carried out according to the protocol of the European 
Malignant Hyperthermia study group.16 Briefly, static tests were performed 
with successively increasing concentrations of caffeine (mM) and halothane 
(%). The cumulative dose-response reaction was obtained and the lowest con­
centration of caffeine and halothane producing a sustained contracture of 0.2 
g was considered the threshold concentration. Threshold of 2 mM or less caf­
feine and 2% or less halothane were considered positive. The dynamic halo­
thane test was performed by exposing the muscle fascicle to increasing con­
centrations of halothane keeping it at a fixed muscle length and relaxing it to 
the initial length after 3 minutes.4 
The test is positive when a concentration of 2% (0,44 mmol/1) or less halo­
thane increases the muscle tension with at least 0,002 N compared to the ten­
sion in absence of halothane. For histopathologic studies, frozen sections of 
muscles were stained using routine techniques. For electron microscopy on 
muscle biopsy of patient 1 thin muscle sections were prepared and double-
stained with uranyl acetate and lead citrate according to standard procedures. 
In cultured muscle cells of patient 1 the cytoplasmic calcium ion concentra­
tion was measured using the fluorescent probe Quin-2.17 The response of 
myoplasmic calcium ion to addition of 1 mM calcium chloride and caffeine 
and halothane to the cultured medium was determined. 
Results 
The ischemic forearm test in all patients showed a normal rise of venous lac­
tate and ammonia. The level of plasma K+ immediately after muscular exer­
cise was determined twice in patient 1 and found to be abnormally high 
increased, as presented in FIGURE 2. Normal values in all patients were found 
for carnitine palmitoyltransferase 1 and 11 in leukocytes, carnitine in serum 
and in muscle biopsy, and for organic acids in urine in all patients. 
Skeletal muscle biopsy samples of all patients were examined histologically 
and all were found to exhibit non-specific myopathic features such as 
increased numbers of fibres with internal nuclei and diameter variability. In 
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FIGURE 2. Relation between the increase of plasma lactate and potassium concentra­
tion upon ischemic forearm exercise determined twice in patient 1 (*) and 
in healthy volunteers (U). 
patient 6 muscle biopsy showed ring bundles which frequently occur in the 
muscle specimen of мн-susceptible patients.4 
Histological studies revealed no glycogen or lipid accumulation. The histo-
chemical reactions of myoadenyl deaminase and Phosphorylase were positive. 
Electron microscopically in patient 1 the regular pattern of myofibrils was 
seriously disturbed by local accumulations of homogenous material of low 
density (FIGURE 3). Light microscopical study in this specimen did not reveal 
these accumulations, so histochemical study could not be performed. 
The biochemical studies of the muscle specimens revealed normal oxidation 
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FIGURE 3. Electron micrograph of muscle biopsy in patient 1. The regular pattern of 
myofibrils is disturbed by accumulations of homogenous material of low 
density. 
rates of pyruvate, normal values for free and esterified carnitine, normal activ­
ities of carnitine palmitoyltransferase 1 and 11 and cytochrome-c-oxidase. 
Two different cultures from muscle biopsies from patient 1 showed a normal 
resting concentration of cytoplasmic calcium of 92 n M and 100 n M respec­
tively (controls 92 ± 8 nM, η = 12). After exposure to 1 m M Ca 2 + this concen­
tration increased by 179 and 159 n M respectively (controls 76 + 19 nM). The 
Ca 2 + concentration did not change at addition of 1,9 m M halothane (FIGURE 
4), but increased by 25 nM at addition of 5 m M caffeine (increase in controls 
i 8 ± i o n M ) . 
The in vitro contraction test was positive in five of these six patients. Positive 
in patients 1-4 and 6, negative in patient 5. The threshold values for caffeine 
and halothane are presented in TABLE 2. 
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table LTreshold values for IVCT. 
Threshold values for in vitro contraction test with caffeine (mM) and halothane 
(%) in patients 1-6. The test is positive when the threshold for caffeine < 2 mM 
and for halothane < 2% (0,44 mmolll). 
Patient threshold caffeine mM threshold halothane % 
I 
2 
3 
4 
5 
6 
Discussion 
2.0 
1.0 
2.0 
0.5 
>4.o 
M 
I.о 
ΐ·5 
n.d. 
2.0 
n.d. 
0.5 
Five of the six consecutive patients with recurrent and unexplained rhabdom-
yolysis had a positive in vitro contraction test for мн. 
In patient 1 the mode of inheritance appears to be autosomal dominant. The 
etiological factor which provokes these recurrent attacks of rhabdomyolysis 
remains unknown. However, the positive in vitro contraction test and the 
increased calcium influx in cultured muscle cells as a response to extracellular 
calcium overload, indicate a failure in calcium homeostasis as the common 
pathogenetic factor. The abnormally high increase of plasma K+ upon muscu­
lar exercise may be due to changes in the Ca2+-activated K+-channels. The 
role of calcium has also been suggested in the etiology of the malignant hyper­
thermia syndrome, which is attended with muscle rigidity and rhabdomyo­
lysis. 
In patient 2 and his family members, the rhabdomyolytic attacks are partly 
induced by anesthetics, partly not. Patient 2 was identified as мн-susceptible 
in the in vitro contraction test. We cannot conclude that his family members 
are мн-susceptible because г ст was not performed on them. However, we 
consider them at risk because of their own previous experience of muscle 
contractures following anesthesia. 
In patients 1, 3, 4 and 6 the attacks of rhabdomyolysis are not induced by 
anesthetics, but by fever, exertion, stress and emotion. Their clinical picture 
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cates [Ca2+] in control cells after the addition of CaCl . 
shows much resemblance to that of Leshner's patients with non-anesthetic-
induced myoglobinuria and of Kelemen's patient who suffered from the so 
called ambulatory мн syndrome. ' 7 
The patients 1-4 and 6 with a positive in vitro contraction test may be con­
sidered at risk for malignant hyperthermia. The anesthetic complications in 
patient 2 and his family members support this view. It does not imply that 
these patients suffer from the same metabolic defect; the rhabdomyolytic 
attacks are probably the expression of disorders of different origins. As a varie­
ty of neuromuscular disorders have been associated with мн-susceptibility,18 
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these patients may also suffer from metabolic or genetic defects resulting in a 
positive г ст without actually being at risk for malignant hyperthermia. The 
underlying defects may share a common pathogenetic factor, probably con­
cerning calcium homeostasis, with malignant hyperthermia. A sequence of 
events takes place which starts with an increased net influx of calcium and 
ultimately leads to muscle cell necrosis; the final common path of muscle cell 
necrosis in several neuromuscular diseases appears to be independant of the 
underlying etiologies.19 
The disturbance in calcium homeostasis may be located either in the plasma 
membrane or in the sarcoplasmic reticulum. The positive effect of dantrolene 
sodium in MH and in Kelcmen's patient with ambulatory мн pleads for the 
latter, as its effect is attributed to diminishing the calcium release from sarco­
plasmic reticulum. The risk of мн-susceptibility implies that prophylaxis 
with dantrolene sodium has to be advised for these patients, whenever they 
undergo anesthesia. In case they develop frequent and severe attacks of rhab-
domyolysis, daily administration of dantrolene sodium may also be effective. 
We reported previously the beneficial effect of dantrolene sodium in a patient 
who suffered from recurrent attacks of exertional rhabdomyolysis.20 Bio­
chemical findings in that patient showed a loosely coupled oxidative phos­
phorylation in mitochondria. She experienced a complete prevention of rhab-
domyolytic attacks since the administration of dantrolene sodium 50 mg t.i.d. 
The causative relation between an increased calcium influx and muscle cell 
necrosis is given support by the findings in patient 1. In this patient we were 
able to demonstrate a disturbance in calcium homeostasis in cultured muscle 
cells. The resting myoplasmic calcium concentration was normal but rose to 
abnormally high levels in response to an overload of extracellular calcium. 
The abnormal K+-increase upon exercise may also be considered as a conse­
quence of a failure in the regulation of the calcium activated K+-channels. 
In conclusion a positive г ст in 5 out of these 6 patients suggests that the asso­
ciation between unexplained non-anesthetic-induced rhabdomyolysis and 
мн-susceptibility is not exceptionally rare. This is also given support by the 
investigation of Wedel and Engel,21 who found in 36% of 30 patients with 
idiopathic hypercKemia a positive in vitro contraction test for мн. 
Whenever the gene for мн will have been isolated, the question can be 
answered with certainty whether these patients actually suffer from мн. For 
the time being, in patients with unexplained and recurrent rhabdomyolysis 
the possibility of MH susceptibility should be considered. 
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Delayed development of exercise-induced 
contractures by dantrolene sodium 
P.J.E. Poels, D.F. Sregeman and F.J.M. Gabreëls 
submitted for publication 
Summary 
The effect of dantrolene sodium on the development of electrically silent 
contractures and associated changes in the muscle membrane excitability was 
studied. Rats with a glycolytic block, induced by iodoacetate, performed 
electrically stimulated ischemic exercise. Dantrolene sodium had a positive 
effect upon the exhaustibility of the electrical motor response to nerve stimu-
lation and prevented electrically silent contractures. 
no 
ELECTRICALLY SILENT CONTRACTURES 
Introduction 
Exercised-induced muscle stiffness, painful muscle contractures and rhab-
domyolysis belong to the clinical features of McArdle's disease and other 
glycogenolytic disorders. During these muscle contractures electromyo-
graphical activity is absent. Accumulation of intracellular calcium is supposed 
to play an important role in the development of the electrically silent contrac-
tures and muscle cell necrosis.1 
Dantrolene sodium is a direct acting muscle relaxant which impairs muscle 
contraction by interfering with the release of calcium from the sarcoplasmic 
reticulum.2 Several studies have suggested a therapeutic role for dantrolene 
sodium in treating exertional myalgia, painful muscle contractures and rhab-
domyolysis.3,4'5'6 
The development of electrically silent contractures has been studied by Brum-
back in an animal model of human defective muscle glycolysis.7,7a In this ani-
mal model the defect of muscle glycolysis was induced by iodoacetate, which 
selectively inhibits the glycolytic enzyme glyceraldehyde-3-p-dehydrogenase 
in vivo with preservation of other enzymatic function.8 
We studied the therapeutic effect of dantrolene sodium on the development 
of electrically silent contractures in rats with a defective muscle glycolysis. 
Materials and methods 
An electrophysiological study of 33 male whistar rats was performed according 
to the procedures of the animal model as described by Brumback.7 In these 
rats a defect of muscle glycolysis was induced by iodoacetate. Subsequently, 
exercise of the left hindleg was performed with sciatic electrical stimulation 
and under ischemic condition. Full details of the experimental procedure are 
described by Brumback.7,73 
During the experiment deep body temperature was maintained between 35-
37°C by means of a heating coil placed beneath the animal. All rats were 
anesthetized with intraperitoneal pentobarbital. Through a midline incision 
in the abdomen the aorta was exposed and a ligature was placed around the 
abdominal aorta below the origin of the renal arteries. Traction was applied to 
the ligature in order to occlude the aortic bloodflow during 60 seconds when 
a solution of iodoacetate was selectively delivered into the the distal aorta. 
Then the abdominal wall was surgically closed and the ligature left in situ. 
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The solution of iodoacetate was prepared by dissolving iodoacetate (Merck) 
in saline and adjusting the pH to 7,4. The effective range of iodoacetate 
proved to be between 25 and 50 mg/kg. A lower dose had little or no effect on 
muscle activity, whereas a higher dose caused irreversible muscle damage. We 
used the solution of iodoacetate in two different doses: one half of the rats 
received 37,5 mg/kg and the other half 50 mg/kg iodoacetate. Five control rats 
underwent the same procedures, but received normal saline instead of iodoac-
etate. 
One hour after the administration of iodoacetate or saline the left sciatic 
nerve was exposed and a hook wire stimulating electrode device placed 
around the nerve. In addition two monopolar needle EMG electrodes were 
placed in the tibialis anterior muscle for recording. Electrical stimuli (50 ¡Js 
duration) were delivered during 4 minutes while simultaneously traction was 
applied to the ligature around the distal aorta. The bloodflow was temporari-
ly occluded for ischemic purpose. Supramaximal stimuli with an amplitude of 
10 times the motor response threshold were given at a frequency of 5 per sec-
ond. Electrical stimulation was stopped after 4 minutes or when electrical 
activity completely had extinguished during stimulation. In Brumback's 
experiment muscle contractures in ischemically exercised rats occured already 
within 1 minute. Then the electrical activity was still recordable. In our study 
electrical stimulation was continued during 4 minutes or until all electrical 
activity had stopped. 
The electrical muscle activity in the form of evoked compound muscle action 
potentials (CMAPS) was amplified and filtered between 1,6 Hz and 8 kHz by a 
Medelec AA6 MKIII EMG amplifier, displayed on an oscilloscope and registered 
on FM tape recorder (Hewlett Packard type 3960). The signal was digitized (12 
bits) into a DEC PDP и/34 laboratory computer with an AR И A/D convenor for 
analysis. 
FIGURE 1 illustrates the definition of the three categories of possible electrical 
responses that were recorded. The muscle electrical response was defined pos­
itive when the amplitude of the evoked CMAPS was still recordable after 4 min­
utes of stimulation (IA). When the amplitude of the evoked CMAPS had faded 
out within 4 minutes of stimulation, the electrical response was defined extin­
guishing (IB). When no electrical activity was recorded, the electrical response 
was negative (ic). 
One hour before iodoacetate was delivered, one part of the rats (group A, 
n=i4) was pretreated with dantrolene sodium in a dose of 5 mg/kg. The other 
part (group B, n=i<p) did not receive dantrolene sodium. The five control rats 
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FIGURE i. Illustration of the three categories of amplitude course of electrical motor 
responses that were recorded. Amplitudes of the CMAPS were still record­
able after 4 minutes in A (positive), fading out within 4 minutes in в 
(extinguishing), or not elicitable in с (negative). 
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were pretreated with dantrolene sodium. The CMAPS in rats of group A were 
compared to those of group в. The latencies and the amplitudes of each CMAP 
were determined using a computerized wave form analysis procedure, espe­
cially developed for this study. The latency was defined as the time between 
the stimulus onset and the appearance of the first local maximum in the 
CMAP. The results of the latencies were compared statistically using the 
unpaired t-test and the amplitudes using analysis of variance. 
After the experiment the rats had to be sacrificed because of surgical wounds 
and the extensive muscle damage. 
Results 
In five control rats the electrical motor responses of the ischemically exercised 
tibialis anterior muscle were positive, i.e. the muscle electrical activity 
remained unimpaired during 4 minutes of stimulation. The muscle contrac­
tions remained clearly observable and showed no visible change during 
electrical stimulation. These control rats did not develop hard muscle 
contractures nor stiffness of the hindleg muscles. 
The electrical motor responses in the 14 rats of group A were positive in 36%, 
table I. Amplitude course of CMAPs. 
Amplitude course of CMAPS during 4 minutes ofstimuUtion in rats treated with 
iodoacetate and dantrolene sodium (group A) and rats treated with iodoacetate 
and no dantrolene sodium (group в). Rats of group с are controh. The difference 
in responses between group A and в is statistically significant (p< 0,0$), tested by 
variance analysis. 
(for classification: FIGURE I) 
iodoacetate 
dantrolene sodium 
positive 
extinguishing 
negative 
group A 
(11=14) 
+ 
+ 
5 (36%) 
8 (57%) 
ι ( 7%) 
group в 
(n=i9) 
+ 
0 ( 0 % ) 
10 (53%) 
9 (47%) 
group с 
(n=5) 
+ 
5 (100%) 
0 
0 
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table 2. Amplitudo course ofCMAPs in group B. 
Amplitudo course of CMAPS in rats without dantrolene sodium (group ъ) treated 
with iodocetate in a low dose of 37,5 mg/kg and high dose of 50 mg/kg respectively. 
iodoacetate low dose 
(n= 10) 
high dose 
(n=9) 
extinguishing 
negative 
2 
7 
negative in 7% and extinguishing in 57% (TABLE I ) . No hard contractures nor 
stiffness of muscles occurred in the rats of group A. 
In the 19 rats of group в the electrical motor responses were extinguishing in 
53% and negative in 47% (TABLE I) . Hard contractures and stiffness in hindleg 
muscles could be palpated before sciatic nerve stimulation and persisted dur­
ing and after the stimulation in 11 of the 19 rats of group в. 
The difference in the amplitude course of the CMAPS between the rats of group 
A and в was statistically significant (p< 0.05). In the rats of group в the electri­
cal motor responses correlated with the dose of iodoacetate. In 10 of the 19 
rats of group в with the lower dose iodoacetate of 37,5 mg/kg the CMAPS extin­
guished within 4 minutes in 8 rats and were negative in 2. In the remaining 9 
of the 19 rats of group в treated with the higher dose iodoacetate of 50 mg/kg 
the CMAPS extinguished in 2 and were negative in 7 rats (TABLE 2). No such 
dose-dependent effect of iodoacetate could be demonstrated in the rats of 
group A. 
In rats of group A the electrical motor responses were positive or extinguishing 
in 13 out of 14 rats and 9 of these CMAPS were suitable for further analysis. In 
rats of group в the motor responses in 10 out of 19 rats could be analysed. In 
control rats no increase in latencies during electrical stimulation could be 
demonstrated. Analysis of the CMAPS of rats of group A and в showed 
increasing latencies during 4 minutes of electrical stimulation (TABLE 3). After 
2 minutes of stimulation, the increase in the mean latencies was less in the rats 
of group A, but because of the large standard deviation not at a significant 
level (p< 0.09). The relative increase in latencies after 2 minutes of stimula­
tion was also smaller in rats of group A, but the difference was statistically not 
significant either (p< 0.06). No dose-effect of iodoacetate on this parameter 
was found. 
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table & Changes in mean tötendes in ÇMAPSÎ 
Changes in mean Utencies in CMAPÍ afier2 minutes ofstimuUtion in group А апаъ. 
Rats of group с are controL·. 
group A group в g r°up с 
iodoacetate 
dantrolene sodium 
mean increase in 
latency at 2' 
relative mean 
increase latency 
+ 
+ 
о.5±о.з(п=9) 
2 0 % 
+ 
-
i .o±o.7 (n=io) 
46% 
_ 
+ 
0 (n=5) 
0 % 
Discussion 
Our study was methodologically based upon the animal model described by 
Brumback.7'73 This model shows similarities with human glyco(geno)lytic 
disorders such as myophosphorylase deficiency and phosphofructokinase 
deficiency. Muscle fiber damage in Brumback's study was evident from 10-
fold CK elevation and scintiphoto scanning with excessive uptake of calcium 
in exercised muscles. His histological studies demonstrated that iodoacetate 
selectively inhibits glyceraldehyde-3-phosphate. The validity of this animal 
model made it suitable for further research and therapeutic intervention stud­
ies. It enabled us to study rats with a defect of muscle glycolysis and to test the 
effect of dantrolene sodium on electrically silent contractures. Ischemic exer­
cise in glycolytic deficient rats results in electrically silent muscle contractions 
and muscle fiber damage, analogous to the ischemic forearm test in human 
glyco(geno)lytic disorders. It was the aim of our study to perform electro­
physiological investigations on the muscle excitability in rats with a defective 
muscle glyco (geno) lysis performing electrically stimulated exercise under 
ischemic condition. The electrophysiological results of our study are in accor­
dance with Brumback's results. 
Dantrolene sodium proved to have a protective effect against the develop­
ment of electrically silent contractures. The evoked CMAPS in rats pretreated 
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with dantrolene sodium were recordable in all except in one case. The excit-
ability of the muscle fiber membrane was preserved for a time longer than in 
rats without dantrolene sodium pretreatment. 
The increase in the initial latencies of the evoked CMAPS after 2 minutes of 
stimulation in the dantrolene sodium rats was smaller than in the rats without 
dantrolene sodium. The electrical excitability of muscle fiber membrane in 
the rats pretreated with dantrolene sodium proved to be more resistant to the 
metabolic block of iodoacetate than in the rats without dantrolene sodium. 
The electrically silent contractures and the development of contractile failure 
may be related to a failure of the excitability of the muscle fiber membrane.9 
On the other hand, the muscle damage may mainly be due to a disturbance in 
energy production. One argument in favour of the latter hypothesis is the 
beneficial effect of dantrolene sodium. Dantrolene sodium does not act pri-
marily on the electrical properties of muscle fiber membrane. This hypothesis 
is also supported by the study of Braakhekke et ai, who concluded from their 
data that in McArdle's disease primarily there is no failure of the muscle fiber 
membrane, but of the excitation-contraction coupling as a result of dimin-
ished energy supply.10 Linssen et al. showed that during exercise in McArdle's 
disease there are no initial changes in muscle fibre excitability, as the conduc-
tion velocities do not decrease like in normals." Cooper et al. demonstrated 
that the muscle fibre excitability becomes impaired only when a disturbance 
of the excitation-contraction coupling mechanism has become evident.12 
Thus the electrophysiologically observed impairment of muscle fiber excit-
ability in our experiment may be a late phenomenon which depends on the 
global energy crisis in the muscle fiber. This crisis is positively influenced in 
an indirect way by the effect of dantrolene sodium on calcium homeostasis. 
Our results support the evidence from animal studies and clinical case reports 
that dantrolene sodium diminishes exercise-induced muscle damage.3'4,6'13 
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Dantrolene sodium does influence the second 
wind phenomenon in McArdle's disease 
P.J.E. Poels, J.P. Braakhekke, E.M.G. Joosten and D.F. Stegeman 
Journal of the Neurological Sciences 1990; 100:108-112 
Summary 
Five patients with McArdle's disease entered a double-blind placebo-con-
trolled, cross-over study of dantrolene sodium. None of the patients experi-
enced beneficial effect of dantrolene sodium medication. Each patient per-
formed two exercise-tests. Surface electromyography (EMG) during exercise 
tests without medication showed a temporary increase in EMG activity during 
the adaptation phase. Quite unexpectedly however, in view of the negative 
clinical results, this electrophysiological manifestation of muscle fatigue during 
the adaptation phase diminished or disappeared in all patients investigated 
when dantrolene sodium was used. 
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Introduction 
Dantrolene sodium is a well known muscle relaxant for the symptomatic 
relief of spasticity. It is also generally accepted as a specific drug in preventing 
malignant hyperthermia and in treating malignant neuroleptica syndrome.1 
The effect of dantrolene sodium on striated muscles is attributed to decreas-
ing the calcium flux from the sarcoplasmic reticulum and thus impairing the 
starting impulse of the excitation-contraction coupling mechanism.1 
A possible therapeutic role in exertional myalgia has been suggested for dan-
trolene sodium.4,5,6 Bertorini et al. mentioned the positive effect of dantro-
lene sodium in one McArdle patient who suffered from severe muscle cramps 
and myoglobinuria.4 In 1987 we reported the case-history of a patient whose 
recurrent attacks of rhabdomyolysis and exertional myalgia were succesfully 
prevented by dantrolene sodium and who gained a better exercise tolerance.7 
We studied the effect of dantrolene sodium on exertional myalgia and exercise 
intolerance in McArdle's disease (myophosphorylase deficiency). This well-
defined disorder of muscle metabolism causes exertional intolerance, mani-
fested by myalgia, early fatigue, weakness of exercising muscles and pigment-
uria. Almost all patients experience a characteristic "second wind", which 
means that if they rest briefly when these muscular signs first appear, they can 
resume exercising with better endurance. 
In healthy subjects the major fuel during the first 20-30 minutes of exercise is 
glycogen. As McArdle patients lack the possibility to use this fuel several trans-
ient subjective and objective phenomena occur during the first 15 minutes of 
the test. Especially during this phase, called the adaptation phase, a possible 
benefit of dantrolene sodium might be expected. For references and more 
detailed information on the adaptation phase we refer to a previous paper.8 
The results of a double-blind placebo-controlled cross-over study of dantro-
lene sodium in 5 McArdle patients are reported. Surface EMG registrations are 
used as a quantitative measure of muscular function during standardized exer-
cise tests. 
Materials and methods 
Five patients with McArdle's disease entered the trial, two women of 23 and 29 
(patients 2 and 3 in FIGURE 2) and three men of 21, 28 and 41 years of age 
(patients 1, 4 and 5 in FIGURE 2). Myophosphorylase protein on SDS-gel elec-
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trophoresis was absent in these 5 patients. Informed consent was obtained and 
the committee on experiments in humans of the University of Nijmegen saw 
and approved the experimental protocol. 
All the five patients regularly experience exercise intolerance, exertional myal­
gia and pigmenturia. However, none of them is disabled seriously; they can 
lead nearly normal lives. Patients 1, 2 and 5 lead sedentary lives and have 
administrative occupations. Patient 3 is a 29 year old woman working as a 
family nurse and enjoying sport, although most kind of sports are too heavy 
for her. Patient 4 is a 28 year old farmer who continuously performs heavy 
bodily work. 
The patients were randomized into two groups by the hospital pharmacist 
and received capsules labelled "dantrium", containing dantrolene sodium or 
placebo (Norwich Eaton). One group, patients 3 and 5, took dantrolene 
sodium for 6 weeks. The dose was built up in three days to 150 mg a day, 50 
mg t.i.d. The other group, patients 1, 2 and 4, took placebo. After the first 
period the treatment was stopped for 4 weeks. After this drug free period the 
patients took the alternative drug for another 6 weeks. At the end of each 
week of treatment the effect of the drug was evaluated. Positive effects on 
daily activities, exercise tolerance and exertional myalgia were noted. Moder­
ate and serious muscular side-effects of medication were mentioned. The seri­
ous side-effects were scored present if the patient had to stop working, to stay 
at home or to lower the dose. The number of non-muscular side-effects that 
were mentioned spontaneously by the patients were scored as well. The items 
of the weekly evaluation and the way of scoring are given in TABLE I. Serum 
creatine kinase (ск) activity was determined at the end of each week of treat­
ment. 
All 5 patients performed a standardized exercise test at the end of both treat­
ment periods. They exercised on an electrically braked bicycle ergometer, at 
30% vo 2 max during 2 hours after a 12 hours overnight fast. During exercise 
tests heart rate was recorded continuously, blood pressure was measured, ven­
tilation was monitored automatically and blood was sampled from an antecu­
bital vein before, during and after exercise. The surface myoelectric signal of 
the m.vastus lateralis was recorded from the surface of the skin at several inter­
vals during exercise. Patients were asked to rate the maximum perceived exer­
tion according to the Borgscale.9 For details on the exercise test and on the 
analysis of the data we refer to the previous paper.8 Since the number of sub­
jects does not allow relevant statistical analysis, the results will be presented 
descriptively. 
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table I. Muscular and non-muscular si<te~effccts. 
The serious muscular side-effects were scored present (+i) when the patient had to 
stop working, to stay at home or to lower the dose of medication. The maximum 
score for each patient per week was 4, the maximum score for all five patients per 
week was 20. Five non-muscuUr side-effects were mentioned spontaneously by the 
patients and the number of these side-effects was scored (+1) per patient per week. 
muscular side-effects non muscular side-effects 
increase of exertional myalgia 
increased weakness 
heaviness in legs 
heaviness in all limbs 
fatigue 
stomache-ache 
sleepiness 
dizziness 
headache 
Results 
Four of the five patients initially had to reduce the daily dose of 150 mg dan-
trolene sodium to 100 or 75 mg due to the side-effects of dantrolene sodium 
during the first half of the treatment period. Patients 2 and 4 eventually did 
not tolerate a dose higher than 100 mg; patients 1, 3 and 5 took 150 mg daily. 
Positive effects of dantrolene sodium on exercise tolerance were only men-
tioned by patient 3. Patients 1, 4 and 5 also experienced slight positive effects 
of placebo. During dantrolene sodium the patients complained about tired-
ness, stomach-ache, sleepiness and dizziness. Muscle weakness was the main 
muscular complaint which disabled all five patients at the start of the treat-
ment. Increased exertional myalgia was only mentioned occasionally; muscle 
weakness and a heavy feeling in arms and legs were predominantly present 
during the first half of the treatment as shown in FIGURE I. These muscular 
side-effects of dantrolene sodium subsided and disappeared in the last week of 
the treatment. Also during placebo treatment serious muscular and other 
side-effects occurred in all five patients, but to a much lower degree than dur-
ing dantrolene sodium treatment (FIGURE I) . CK levels during both drug treat-
ment periods showed the same continuous fluctuations as before the trial 
except in patient 4 in whom a decrease of CK level of more than 70% was 
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— placebo dantrolene 
sodium 
week no. 
placebo dantrolene 
sodium 
В 
FIGURE i. The scores of the muscular side-effects (A) and non-muscular side-effects 
(в) of all five patients per week during dantrolene sodium and during pla­
cebo treatment. See TABLE I for the score. 
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BBS placebo 
Δ potassium (mmol/) 
E^2 dantrolene 
sodun 
patient no. 
FIGURE 2. Changes in potassium levels after 120 minutes of exercise (level at 
120 minutes minus level at о minutes) for each patient during dan­
trolene sodium and during placebo treatment. 
found during dantrolene sodium treatment, ск level in patient 4 during pla­
cebo ranged from 1,037 t o 3>92° IU/1 whereas during dantrolene sodium ск 
level ranged from 433 to 676 iu/1 (n< 91). 
During the exercise tests a second wind phenomenon was observed in all 
patients, like on previous occasions as described before.8 So in all patients the 
effect of dantrolene sodium on the several physiological processes of the adap­
tation phase could be studied. All patients except patient 3 rated the subjective 
perceived effort higher during dantrolene sodium treatment than during pla­
cebo. 
Potassium levels increased during exercise in all the five patients in the place­
bo period (FIGURE 2). This increase in potassium levels during exercise was 
attenuated during dantrolene sodium treatment in these patients except for 
patient 4. Even a decrease in potassium level during exercise occurred in 
patient 1 when dantrolene sodium was used. The changes in other variables 
(hcartrate, bloodpressure, ventilatory parameters, ammonia and CK levels) 
were not influenced in a consistent way by dantrolene sodium as compared to 
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FIGURE 3. Amplitude course of the m.quadriceps surface EMG of the five 
patients during exercise test at time 0-20 minutes in the placebo (A) 
and in the dantrolene sodium period (в). Amplitudes are expressed 
as percentages of the mean amplitude during minutes 45-120. A 
third degree regression estimate is presented as a solid line. 
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placebo treatment. Only in patient 4 again a decrease of CK level during exer­
cise test of more than 70% was found when dantrolene sodium was used. 
Surface EMG recordings during exercise tests showed a transient increase in 
electrophysiological muscle activity during the adaptation phase when place­
bo was used. Braakhekke et al. observed the same pattern of EMG recordings in 
patients 2, 3 and 5 during previous test situations without any medication.8 
Such change in EMG activity has not been observed in controls during the first 
20 minutes of exercise.8 When dantrolene sodium was used by these McArdle 
patients, this increase in EMG activity during the first 15 minutes was dimin­
ished or absent and a steady state level was reached more gradually, as shown 
in FIGURE 3, where the EMG data of all five patients are collapsed. 
Discussion 
Subjective experiences 
The McArdle patients in this study experienced little or no beneficial effect of 
dantrolene sodium on their daily activities, exercise tolerance and exertional 
myalgia. On the contrary, the possible benefit was largely counteracted by the 
initially discomforting side-effects. Muscular side-effects were most prominent 
at the start of the treatment period, then gradually subsided and definitely 
disappeared in the last week of medication. Exertional myalgia has not been 
affected essentially and muscular weakness was the most discomforting side-
effect in all five patients. The side-effects of placebo were markedly less than 
those of dantrolene sodium. 
In the patient described by Walton, dantrolene sodium slightly lessened the 
muscle pain but had to be discontinued because of unacceptable muscle 
weakness.6 Bertorini et al. however, mentioned that in one McArdle patient a 
dose of 400 mg dantrolene sodium was sufficient to relieve the pain without 
causing muscle weakness or side-effects.4 It is not clear how much time the 
patient took to build up the medication to this daily dose. 
The continuously fluctuating CK level in 4 of 5 patients was not influenced by 
dantrolene sodium nor by placebo. Only patient 4 showed lower ск levels 
during the use of dantrolene sodium than during placebo. On the one hand, 
this lowered CK level in patient 4 may be ascribed to muscle weakness caused 
by dantrolene sodium, which disabled him to perform his usual activities on 
the farm. On the other hand, also during exercise test the ск level in this 
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patient 4 was lower during dantrolene sodium medication. So this finding 
may also be attributed to a protective effect of dantrolene sodium against 
muscle necrosis. 
Exercise testing 
Dantrolene sodium appeared to have a slight adverse effect on perceived exer-
tion in all patients except patient 3. The degree of metabolic stress, as indicat-
ed by changes in ammonia levels,10 was not influenced by dantrolene sodium. 
The increase in potassium levels was attenuated during dantrolene sodium 
treatment in 4 of 5 patients. This finding has also been demonstrated in 
another patient who was treated with dantrolene sodium because of recurrent 
rhabdomyolysis due to Ca2+-ATPase deficiency." It gives support to the 
assumption that dantrolene sodium decreases the calcium influx in exercising 
muscles. It also confirms the observations that an increased intracellular cal-
cium concentration enhances the K+-efflux by stimulating the Ca1+-activated 
K+-channels.12 
Surface electromyography 
The transient increase in EMG activity that occurs during the adaptation phase 
in patients with McArdlc's disease and not in healthy subjects, was described 
before.8 This electrophysiological manifestation of muscle fatigue is due to 
decreased contractile efficiency during the adaptation phase. 
During dantrolene sodium this increase in EMG activity is attenuated or 
absent, indicating that the transient extra recruitment of motor units during 
the adaptation phase still occurs, but to a much lower degree. The normal 
EMG reflections of muscular fatigue during exercise, i.e. a lowered median fre-
quency of the signal, were not found in any of the registrations studied, which 
is also in accordance with the previous findings of Braakhekke et al.s 
It can be hypothesized that dantrolene sodium counteracts the impairment of 
the contractile efficiency during the adaptation phase by preventing too much 
calcium influx from sarcoplasmic reticulum in such a way that there is less 
need for additional recruitment of motor units. 
If dantrolene sodium would give rise to a general muscular weakness by 
reducing both twitch and tetanic muscle tension because of this decreased cal-
cium influx,'3 then an overall increase of surface EMG during dantrolene 
sodium intake might be expected. Our data were not conclusive in this 
respect. 
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Conclusions 
These data indicate that dantrolene sodium had no beneficial effect upon per-
ceived exercise tolerance in McArdle patients during the limited period of 6 
weeks of treatment. However, the attenuation of potassium levels during exer-
cise gives evidence of reduced metabolic stress for the exercising muscles. The 
positive results of surface EMG studies also indicate less physiological problems 
in the adaptation phase during the first 15 minutes of exercise. As all side-
effects of dantrolene sodium disappeared after 5 weeks, it is supposed that a 
more gradual raising of the dantrolene sodium dose and a more prolonged 
period of medication intake may prevent the unacceptable side-effects and 
provide further information about the therapeutic role for dantrolene sodium 
in treating severe exertional intolerance and myalgia. 
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Introduction 
Dantrolene sodium is used as a skeletal muscle relaxant for the symptomatic 
relief of spasticity.5 It is also generally accepted as a specific drug in preventing 
and treating malignant hyperthermia.6 A possible therapeutic role for dantro­
lene sodium has been suggested in exertional muscle pain syndromes.1'14 
We present a patient whose recurrent attacks of exertional rhabdomyolysis 
were succesfully prevented with dantrolene sodium and who also gained a 
better exercice tolerance. 
Case report 
A 52-year-old woman suffering from fatigue and myalgia since early child­
hood was referred to the neurological department. As a young girl, she had 
suffered from severe attacks of muscle pain after assisting her parents with 
heavy fieldwork. From adolescence, she had repeated attacks of myalgia and 
produced dark brown urine once or twice a month. Most attacks were trig­
gered by cold, exertion, menstruation, or fasting. She also complained of stiff 
hands and muscular weakness at rest after moderate exercise. In fact, she was 
restricted in her daily activities because of decreased exercise tolerance. 
The previous medical history mentioned a severe attack of myoglobinuria in 
1974, which had been provoked by an exercise test in the cold and which had 
led to loss of consciousness, severe muscle cramps, and long-lasting myalgia 
afterwards. 
On examination during a spontaneous attack of myoglobinuria, the patient 
showed pitting edema of both legs and generalized muscle pain and weakness, 
also involving the facial muscles. 
Labatory studies disclosed normal serum electrolyte values and normal data 
concerning renal functions. Serum creatine kinase (ск) activity was elevated 
to 12,470 iu/1 on the first day of admission (normal 15-72). Concentrations of 
myoglobin in serum of 8,190 ng/ml (normal< 85) were noted and in urine of 
more than 25,000 ng/ml. The values of total and free carnitine in scrum were 
within normal limits. The ischemic exercise test gave a normal rise of venous 
lactate and ammonia. There was a normal activity of phosphofructokinase in 
erythrocytes and of carnitine palmitoyltransferase in leukocytes. 
Electrocardiography revealed nonspecific s-τ wave changes. Electromyo­
graphy showed a few fasciculations and a shortened duration and decreased 
amplitude of motor units. The basal metabolic rate was normal. 
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Special studies 
In a muscle biopsy taken r month after the myoglobinuric attack no evident 
histopathologic changes could be demonstrated. 
Biochemical studies in muscle biopsy showed normal activities of Phosphoryl­
ase, phosphofructokinase, phosphoglycerate mutase, phosphoglycerate kinase 
and carnitine palmitoyltransferase. Carnitine content was also normal. Bio­
chemical study of mitochondria revealed normal rates for pyruvate oxidation 
and adenosine triphosphate (ATP) production in the presence of exogeneous 
adenosine diphosphate (ADP), but the oxidation rate of pyruvate was too high 
in the absence of exogeneous ADP. These data point to an in vitro loosely cou­
pled state of oxidative phosphorylation. This conclusion was confirmed in a 
second muscle biopsy 1 year later. 
Treatment 
In order to prevent the frequently occuring attacks of rhabdomyolysis, a treat­
ment with dantrolene sodium, 50 mg 3 times daily, was started. No side effects 
of the medication were recorded. Since then, she has had no more attacks of 
myoglobinuria for 5 years. She also reports a marked reduction of the postex­
ercise muscle pain and stiffness. 
Discuss/on 
Dantrolene sodium is known as a specific muscle relaxant and as an effective 
drug in preventing and treating malignant hyperthermia.5,6 It also inhibits the 
clinically insignificant rise of serum ск activity in normals that is usually seen 
after the combined use of triggering anesthetics, such as halothane and succi-
nylcholine.11 Its efficacy in exertional muscle pain syndromes has been sug­
gested.1 
Dantrolene sodium is known to decrease the release of calcium from the sac-
roplasmic reticulum.9 Calcium may play a role in muscle pain, as has been 
suggested in McArdle s disease,2 and in the development of malignant hyper­
thermia.'3 Muscle cell necrosis is also explained by an increased calcium influx 
into the cell, triggering a vicious cycle of mitochondrial overloading and ener­
gy depletion, which leads to hypercontraction and finally to cell death.4,15 
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It is very remarkable that in our patient, dantrolene sodium has provided a 
complete prevention of myoglobinuria attacks for 5 years. Before therapy, 
these attacks occured once or twice a month since childhood. 
Biochemical findings in this patient point to a state of loosely coupled mito-
chondria. The first record of a patient with this mitochondrial disorder and 
nonthyroid hypermetabolism was published in 1962 by Luft et al} Since then, 
several patients have been described who suffered from loosely coupled mito-
chondria without signs of hypermetabolism,10·12 which also holds for our 
patient. Whether dantrolene sodium is able to exert an effect on the mito-
chondrial calcium uptake and to influence the coupling of mitochondria 
remains unresolved. Lane et al.7 reported that dantrolene sodium did not 
appear to have a beneficial effect in McArdle's disease. The findings in our 
patient however, support the view of Brumback and Gerst,3 that dantrolene 
sodium might be of therapeutic use in individual cases of recurrent exertional 
rhabdomyolysis. 
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GENERAL DISCUSSION 
In this thesis some clinical and etiological aspects of rhabdomyolysis are pre-
sented. The subject is introduced in CHAPTER 2 by reviewing the literature 
with respect to the clinical and biochemical features, the complications, the 
etiology and the treatment of rhabdomyolysis. 
Rhabdomyolysis is defined as a clinical and biochemical syndrome, resulting 
from acute destruction of striated musculature. Muscle necrosis causes myal-
gia, contractures, muscle swelling and weakness, and a substantial release of 
muscle cell contents into the circulation. Increased serum levels of creatine 
kinase and myoglobin with subsequently detectable amounts of myoglobin in 
urine are the hallmarks of the laboratory examination. The criteria for the 
diagnosis rhabdomyolysis related to the height of the increased CK activity is 
rather arbitrary. Most authors refer to a level of at least five fold the normal 
value in association with the clinical muscular signs and symptoms and myo-
globinuria.1 
As appears from the many case reports in literature, rhabdomyolysis is not a 
rare disorder. The incidence and prevalence of rhabdomyolysis have not 
exactly come to our knowledge. This is probably due to the fact that a num-
ber of patients, especially those with mild and recurrent attacks of rhabdo-
myolysis, do not necessarily search for medical attendance. 
In patients with chronic muscular complaints about exercise-intolerance, 
myalgia and muscle weakness, the diagnosis of rhabdomyolysis should be 
considered. It is known that several hereditary disorders of metabolism are 
characterized by recurrent exertional rhabdomyolysis. Elevated levels of 
serum CK and myoglobinuria have proven to be important indices in the diag-
nosis of several neuromuscular disorders with specific enzyme defects. 
In case of severe rhabdomyolysis the clinical picture may be dominated by the 
major complications of rhabdomyolysis which consist of acute renal failure, 
general internal disturbances, cardiac arhythmia and the compartmental syn-
drome. Rapid recognition of rhabdomyolysis in the early phase, immediate 
medical attendance and prevention of its potentially lethal complications are 
the concern of several medical specialists, in particular the neurologist and 
internist. 
A great number of endogenous and exogenous disorders can induce rhab-
domyolysis, as described in CHAPTER 2. An increasing number of molecular 
biochemical defects of the energy metabolism has been recognized in the last 
decades. However, in only half of the muscle biopsies of patients with unex-
plained rhabdomyolysis, specific enzyme defects have been found.1 
It was our aim to recognize new etiological factors in the classification of 
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rhabdomyolytic syndromes with a more or less well circumscribed biochemi­
cal defect and to add some more etiologies to the known hereditary and 
acquired causes of rhabdomyolysis. Subsequently an attempt was made to 
prevent or ameliorate the process of muscle necrosis in patients with recurrent 
attacks of rhabdomyolysis. 
Section ι of this thesis deals with patients suffering from unexplained attacks 
of rhabdomyolysis. In the four patients described in CHAPTER 3.1-3.4 new and 
up till now unknown etiologies of rhabdomyolysis have been found. 
In CHAPTER 3.1 rhabdomyolysis is described in an adult male with a secondary 
carnitine deficiency. The clinical presentation consisted of rhabdomyolysis, 
acute encephalopathy and moderate renal insufficiency, provoked by exertion 
and fasting. The metabolic disorder proved to be a medium-chain acyl-CoA 
dehydrogenase (MCAD) deficiency, an inborn error of metabolism with disturb­
ance in the fatty acid oxidation. The diagnosis was suspected because of a 
decreased concentration of serum and muscle carnitine. The diagnosis was 
established by measuring the oxidation rates of medium-chain fatty acids, 
MCAD activity in muscle specimen and analyzing the urinary excretion of 
esterified carnitine. Genomic DNA studies revealed a point mutation of the 
MCAD CDNA. The patient was succesfully treated with L-carnitine. The main 
advice to avoid fasting and use a diet with moderate restriction of fat prevent­
ed further attacks of rhabdomyolysis. Rhabdomyolysis in this patient with 
MCAD deficiency was considered as the result of the impaired beta-oxidation 
of fatty acids in mitochondria. The encephalopathy was attributed to the 
diminished supply of ketone bodies to the brain. The impaired oxidation of 
octanoate may also have contributed to the development of encephalopathy. 
Accumulating evidence suggests that MCAD deficiency is relatively common 
with more than 100 known cases in literature, although many cases probably 
remain unidentified.3 The age of initial presentation varies widely with some 
patients presenting acutely in early infancy with all the features resembling 
Reye's syndrome, while others present as adults primarily with hypoglycaemic 
episodes or muscular weakness. The attacks are provoked by stress, fever, viral 
illness and fasting. At adult age, rhabdomyolysis has never before been asso­
ciated with MCAD deficiency. 
When a disturbance of lipid metabolism is suspected, defects of fatty oxida­
tion should be considered high upon the list of potential causes. As MCAD 
deficiency is the commonest of these disorders, it should be added to the 
hereditary causes of rhabdomyolysis. 
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In CHAPTER 3.2 a patient with a dual viral infection is described. Acute rhab-
domyolysis has been associated before with a number of viral infections. Of 
these only Influenza A and в, adenovirus type 2 and Coxsackie-virus type A9 
have been isolated from muscle tissue. The patient described suffered from a 
dual infection of Epstein Barr virus (EBV) and echovirus 6. EBV was clinically 
suspected and identified serologically, while echovirus 6 was isolated from 
muscle, EBV infection is a common disorder in the population, yet any direct 
causal relationship between EBV and rhabdomyolysis has not been document­
ed. Echovirus 6 has not been reported either as a direct agens in rhabdomyo­
lysis. 
We hypothesized that these two infections have interacted synergetically. We 
considered the possibility that the EBV infection has altered the patient's 
immune system and made him more susceptible to the infestation of echo-
virus 6 in muscle tissue. 
In CHAPTER 3.3 rhabdomyolysis is described in a patient with malaria tertiana 
and myoadenylate deaminase (MAD) deficiency. While Malaria tertiana, due 
to plasmodium vivax, is no rare disease in tropical countries, it has never been 
associated with rhabdomyolysis. The patient was treated with chloroquine 
and made a good recovery. Additionally, MAD deficiency was demonstrated by 
means of a standardized ischemic exercise test and histochemical study of 
muscle biopsy, MAD deficiency, a disorder of ATP metabolism, has been found 
coincidentally in several well classified neuromuscular disorders. The major­
ity of patients have exercise-related symptoms. In this patient however, there 
was no evidence of any neuromuscular disease. In general, MAD deficiency has 
little serious consequences, as many patients are non-symptomatic or have 
symptoms only in concert with other abnormalities.4 In the patient described 
the clinical picture was predominated by the infection with the protozoan 
Plasmodium vivax. 
Also in this case, we proposed a mechanism of synergetical interaction 
between the two disorders probably resulting into rhabdomyolysis. MAD defi­
ciency as underlying metabolic disorder was considered as a co-factor in the 
development of rhabdomyolysis. The contribution of chloroquine as myotox-
ic agent could not definitely be excluded. 
In CHAPTER 3.4 a patient is described who suffered from exercise-intolerance, 
relaxation problems of skeletal muscles and recurrent attacks of rhabdomyoly­
sis. The patient was found to have a Ca2+-ATPase deficiency. The diagnosis 
was established by measuring the activity of sarcoplasmic reticular Ca2+-
ATPase in muscle homogenate. Ca2+-ATPase deficiency is a rare disorder of 
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muscle metabolism, first described by Brody in 1969.5 Rhabdomyolysis has 
not yet been associated with this enzyme deficiency, which may be attributed 
to the very small number of patients reported up till now. In addition, this 
patient performed standardized ischemic exercise tests which resulted in an 
abnormal increase of potassium concentration in the venous effluent of 
contracting muscles. This abnormal K+-efflux was considered as a result of an 
impaired function of the Ca2+-activated K+-channels. During treatment with 
dantrolene sodium this K+-efflux was remarkably reduced. Treatment with 
dantrolene sodium reduced the exertional myalgia and prevented further 
attacks of rhabdomyolysis. 
From the results of investigations in these four patients it can be concluded 
that the etiology of rhabdomyolysis consists of a great variety of causative fac-
tors. Moreover, the etiology may be multifactorial and rhabdomyolysis may 
result from a synergetic interaction of different agents. 
The diagnosis rhabdomyolysis should be considered when a patient presents 
with symptoms of myalgia, muscle weakness, exercise-intolerance, and pig-
menturia. In emergency cases, however, the clinical picture may be dominat-
ed by severe muscle weakness, fever, metabolic disturbances and encephalo-
pathy. When the diagnosis rhabdomyolysis is suspected, an accurate medical 
history should be directed to the muscular symptoms, the triggering factors, 
the accompanying circumstances, the recurrency of symptoms and the pres-
ence of pigmenturia. Attention should be given to signs of muscle weakness, 
swelling and tenderness. The diagnosis in the acute phase can be established 
by determination of increased concentrations of serum CK and myoglobin, 
and a detectable amount of myoglobin in urine. 
In acute and severe rhabdomyolysis special attention should be given to the 
major complications of rhabdomyolysis: acute renal insufficiency, general 
metabolic disturbances and the compartmental syndrome. Examination of 
the acquired pathogenetic factors of rhabdomyolysis should include toxic, 
traumatic, mechanical, ischemic, infectious agents, as well as internal meta-
bolic diseases, heat-related syndromes and sudden changes in prescribed med-
ication. Therapeutic measures in the acute situation depend on the etiology 
of rhabdomyolysis and consist of withdrawal of causative agents, treatment of 
infections, control of electrolytes, maintenance of adequate circulation, suffi-
cient diuresis, and control of muscle tissue pressure. 
In case of recurrent exertional rhabdomyolysis a metabolic cause should be 
suspected. The family history and pedigree are of important diagnostic value. 
Laboratory investigation includes determination of carnitine, carnitine pal-
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mitoyltransferase ι and и and glycolytic enzymes in erythrocytes, and urinary 
analysis of organic acids and acylcarnitines. Special tests, when a metabolic 
disorders is suspected, include an ischemic exercise test for the diagnosis of 
glyco(gen)lytic enzyme deficiencies and MAD deficiency, and a phenylpropio-
nacid loading test for MCAD deficiency.6 For histological, histochemical, 
electronmicroscopic study and virus isolation a needle muscle biopsy should 
be performed. Strong evidence of a metabolic myopathy justifies a muscle 
biopsy for biochemical study of lipid and mitochondrial metabolism and cal­
cium homeostasis, and the in vitro contraction test (г ст) for мн-susceptibil-
ity. 
Section π of the thesis focuses on the role of calcium homeostasis in the 
pathogenesis of muscle necrosis and the therapeutic value of dantrolene 
sodium in the prevention of rhabdomyolysis. 
A comparison was made to the syndrome of malignant hyperthermia (мн), a 
potentially fatal disorder affecting skeletal muscle. Malignant hyperthermia is 
characterized by an accelerated aerobic and anaerobic metabolism in skeletal 
muscle, with rapidly rising body temperature, metabolic and respiratory aci­
dosis, muscle rigidity and rhabdomyolysis.7 The concentrations of serum 
electrolytes, creatine kinase and myoglobin are elevated. There is increasing 
evidence that the primary defect lies within the calcium release mechanism of 
muscle cell.8 A breakdown in the mechanism regulating calcium influx into 
cytoplasm is also presumed to underly the development of rhabdomyolysis. 
In CHAPTER 4.1 six patients are described with unexplained recurrent rhab­
domyolysis who were investigated with the in vitro contraction test (г ст) for 
MH-susceptibility. In five of them the IVCT was positive, suggesting that the 
association between rhabdomyolysis and мн susceptibility is not exceptional­
ly rare. It cannot be concluded that these patients actually suffer from malig­
nant hyperthermia, or ever will, but in patients with unexplained and recur­
rent rhabdomyolysis, the possibility of мн susceptibility should be taken into 
account. 
The hypothesis that the underlying defect in rhabdomyolysis may share a 
common pathogenetic factor with мн, concerning calcium homeostasis, was 
supported by the positive г ст in patients with recurrent rhabdomyolysis. A 
second argument resulted from the study of calcium homeostasis in cultured 
muscle cells in one of these patients with a positive г ст. The concentration 
of free cytoplasmic calcium increased after exposure to extracellular calcium 
overload to abnormally high levels as compared to controls. A third argument 
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for a failure in calcium homeostasis in exertional rhabdomyolysis was pro-
vided by the investigations in the patient described in CHAPTER 3.4, in whom 
a Ca2+-ATPase deficiency and an abnormal rise of potassium in venous effluent 
of contracting muscles was found. 
Recognizing the important role of calcium homeostasis in the development of 
rhabdomyolysis, the possibility was explored to influence the process of mus-
cle necrosis pharmacologically with a calcium antagonist. Analogous to the 
use of dantrolene sodium in malignant hyperthermia, a therapeutic effect of 
dantrolene sodium in the prevention of recurrent rhabdomyolysis was 
assumed. 
Dantrolene sodium is a direct muscle relaxant with an inhibitory effect on the 
influx of free calcium into cytoplasm of exercising muscles.9 The effect of 
dantrolene sodium was studied in two experiments. 
In CHAPTER 4.2 a study is described in male whistar rats with an induced gly-
colytic block, in which muscle contraction was achieved by electrical nerve 
stimulation. One group of rats was pretreated with dantrolene sodium. In rats 
without dantrolene sodium hard contractures and muscle stiffness developed. 
With surface EMG the electrical motor responses were recorded and compared 
for both groups. The evoked compound muscle action potentials in rats with 
dantrolene sodium could be recorded in all except one case. The excitability 
of the muscle fiber membrane was preserved for a longer time, than in rats 
without dantrolene sodium. The electrophysiologically observed impairment 
of muscle fiber excitability was considered as a late phenomenon of global 
energy crisis in the muscle fibers. This crisis was positively influenced by dan-
trolene sodium. 
The second experiment, described in CHAPTER 4.3, was a double-blind place-
bo-controlled cross-over study in five patients with McArdle's disease (myo-
phosphorylase deficiency). This well-defined disorder of glycogen 
metabolism is characterized by exertional intolerance, rhabdomyolysis and 
myoglobinuria.10 McArdle patients lack the possibility to use glycogen as 
major fuel during the first 15 minutes of exercise. They experience a character-
istic "second wind phenomenon", which means that if they rest briefly when 
these muscular signs first appear, they can resume exercising with better endu-
rance. Especially during this initial phase of exercise a possible benefit of dan-
trolene sodium was expected. The subjective effects of dantrolene sodium 
were evaluated and for objective measurement two standardized exercise tests 
with recording surface EMG were performed. The patients experienced no 
positive effects of dantrolene sodium but muscle weakness as discomforting 
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side-effect of the medication. This side-effect was most prominent at the start 
of the treatment and gradually disappeared. The muscle weakness was attrib-
uted to the high initial dose of dantrolene sodium and could probably have 
been avoided by a more gradual raising of the dose. The data of the exercise-
tests did not disclose any beneficial effect of dantrolene upon exercise-toler-
ance. On the other hand, biochemically there was evidence of reduced meta-
bolic stress, as was derived from the lesser increase of plasma potassium 
concentration during dantrolene sodium treatment. This supported the 
assumption that dantrolene sodium decreases the influx of free calcium into 
cytoplasm of contracting muscles. During exercise without dantrolene 
sodium, high levels of potassium were found, which is in accordance with the 
observations that an increased intracellular calcium concentration enhances 
the K+-efflux by stimulating the Ca2+-activated K+-channels.n The results of 
the surface EMG studies indicated less physiological problems during the first 
15 minutes of exercise. Previous studies in McArdle patients showed an 
increase in EMG activity during this phase, due to an extra recruitment of 
motor units.12 In our 5 patients this increase in EMG activity, an electrophysio-
logical manifestation of muscle fatigue, diminished or disappeared during 
dantrolene sodium treatment. 
The beneficial effect of dantrolene sodium was also confirmed in the patient, 
described in CHAPTER 3.4, in whom a Caz+-ATPase deficiency was found. He 
suffered from exercise-intolerance, relaxation problems of skeletal muscles 
and recurrent attacks of rhabdomyolysis. Treatment with dantrolene sodium 
reduced the exertional myalgia and prevented further attacks of rhabdomyo-
lysis. When the administration of dantrolene sodium was discontinued, 
because of the experienced side-effects of muscle weakness, the muscular 
symptoms returned. After retaking the medication, the patient was symptom-
free again. This subjective amelioration was confirmed by performing 4 
ischemic exercise-tests, showing an abnormal K+-release from exercising mus-
cles, which normalized during administration of dantrolene sodium. 
The patient described in CHAPTER 4.4 suffered from exertional intolerance 
since childhood and as an adult she experienced severe attacks of rhabdomyo-
lysis. Most attacks were provoked by exertion, cold or fasting. Biochemical 
investigation revealed a loosely coupled state of oxidative phosphorylation, a 
defect of mitochondrial metabolism. A treatment with 3 times 50 mg dantro-
lene sodium reduced the postexercise myalgia and provided a complete pre-
vention of further attacks of rhabdomyolysis. This patient did not experience 
any side-effects of the medication. 
1 « 
CHAPTER 5 
From these studies it is concluded that exertion is the main triggering factor 
of muscle necrosis in patients with recurrent attacks of rhabdomyolysis. Exer-
tional rhabdomyolysis proves to be the manifestation of several defects of 
muscle metabolism. The common pathogenetic factor apparently concerns a 
disturbance in calcium homeostasis, in which a failure in the energy produc-
tion process promotes an increased influx of Ca2+ into cytosol and sets into 
motion cascades of events, eventually resulting in muscle cell necrosis. 
In exertional and recurrent rhabdomyolysis dantrolene sodium may reduce 
exertional myalgia and prevent attacks of rhabdomyolysis. To avoid the side-
effects of muscle weakness, the dose should be started low (i mg/kg) and grad-
ually be built up (2mg/kg). Additional measures and advices in recurrent 
rhabdomyolysis in glyco (geno) lytic deficiencies consist of avoiding extreme 
exertion, while moderate physical training may improve the exercise-toler-
ance.13 In recurrent rhabdomyolysis due to disorders of lipid metabolism, the 
main advice is to avoid fasting and to use a diet with moderate restriction of 
fat consumption and increased supply of carbohydrate. In carnitine deficien-
cy the administration of L-carnitine is generally accepted as a therapy in the 
acute situation. 
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SUMMARY 
This thesis presents the results of a study on rhabdomyolysis. The first part 
concerns the clinical aspects and additional etiological factors of rhabdomyo­
lysis. The second part deals with the role of calcium homeostasis in the pro­
cess of muscle cell necrosis and the prevention of rhabdomyolysis by dantro­
lene sodium. The aim and outline of the study are described in CHAPTER I. 
In CHAPTER 2 the subject is introduced by a review of literature. The clinical 
and biochemical definition of rhabdomyolysis is presented and illustrated by 
a case history. Recent theories about the pathophysiology and pathogenesis of 
muscle cell necrosis are described. Emphasis is put on the clinical symptoms 
of rhabdomyolysis and its major complications. A classification of the causa­
tive factors - both hereditary and acquired causes - are presented. The chapter 
finishes with diagnostic and therapeutic guidelines for the clinician. 
In CHAPTER З four patients are presented who suffer from severe attacks of 
rhabdomyolysis. The investigations in these patients resulted into new etiolog­
ical factors of rhabdomyolysis. These additional etiologies consist of a 
medium-chain acyl-CoA dehydrogenase deficiency with adult onset, a dual 
infection of Epstein-Barr virus and echovirus 6, malaria tertiana in combina­
tion with myoadenylate deaminase deficiency, and Ca*+-ATPase deficiency, a 
disturbance of calcium homeostasis. 
CHAPTER 4 focuses on the role of calcium homeostasis in the development of 
rhabdomyolysis. For this purpose a comparison was made to malignant 
hyperthermia (мн), the most life-threatening form of rhabdomyolysis, in 
which the myoplasmic calcium concentration is abnormally regulated. The 
diagnostic test for мн-susceptibility is the in vitro contraction test (IVCT). In 
CHAPTER 4.1 six patients are presented with unexplained recurrent rhabdo­
myolysis who were tested with the г ст. In five of the six patients the IVCT 
proved to be positive. In one of the patients the calcium homeostasis was 
studied in cultured muscle cells and found to be abnormally regulated. These 
results confirmed the importance of the role of calcium homeostasis in the 
process of rhabdomyolysis. 
Analogous to the use of dantrolene sodium in the treatment of мн, its effect 
was studied in an animal experiment as described in CHAPTER 4.2. Rats with 
an induced glycolytic deficiency were electrically stimulated to muscle 
contraction and developed rhabdomyolysis. In rats that were pretreated with 
dantrolene sodium the development of electrically silent muscle contractures 
was delayed and the excitability of muscle fibre membrane was preserved for a 
longer time than in rats without dantrolene sodium. 
In CHAPTER 4.3 dantrolene sodium is studied in five McArdle patients who 
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easily develop muscle contractures and rhabdomyolysis when they perform 
moderate to strenuous exercise. The energetic problems are most prominent 
during the first io minutes of exercise, before the so-called second wind phe-
nomenon takes place. Electrophysiological studies during exercise tests 
showed that the energy crisis during the first io minutes was positively influ-
enced by dantrolene sodium. Outside these exercise-tests, however, the 
patients experienced initially a temporary muscle weakness, as a side-effect of 
dantrolene sodium. 
A beneficial effect of dantrolene sodium was recorded in a patient with fre-
quent attacks of rhabdomyolysis, due to Ca2+-ATPase deficiency, as described 
in CHAPTER 3.4. Treatment with dantrolene sodium reduced the exertional 
myalgia and prevented further attacks of rhabdomyolysis. When the medica-
tion was stopped, muscle symptoms immediately returned. Ischemic exercise-
tests showed an abnormal potassium release in venous blood of contracting 
muscles as a sign of muscle fatigue. This increased potassium release normal-
ized during treatment with dantrolene sodium. 
In CHAPTER 4.4 the beneficial effect of dantrolene sodium is also demonstrat-
ed in a patient who suffered from exercise-intolerance and frequent attacks of 
rhabdomyolysis. Biochemical investigations revealed a disturbance of mito-
chondrial metabolism. Treatment with dantrolene sodium improved her exer-
cise-tolerance and prevented further attacks of rhabdomyolysis. 
CHAPTER 5 contains a retrospection of the study and a general discussion 
about the results of investigation. Finally, diagnostic and therapeutical guide-
lines are provided for the clinician who deals with the problem of rhabdo-
myolysis. 
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SAMENVATTING 
In dit proefschrift worden de resultaten beschreven van een studie betreffende 
rhabdomyolyse. Het onderzoek had een tweeledige doelstelling, zoals weerge-
geven in HOOFDSTUK i. Enerzijds werd getracht ordening aan te brengen in de 
tot nu toe bekende oorzaken van rhabdomyolyse en werd bij patiënten met 
onverklaarde rhabdomyolyse onderzoek verricht naar mogelijk nieuwe etiolo-
gische factoren. Anderzijds werd de rol van de intracellulaire calcium regulatie 
in het proces van spiervezel necrose bestudeerd en onderzoek verricht naar de 
werking van dantroleen ter preventie van recidiverende rhabdomyolyse. 
HOOFDSTUK 2 bevat een overzicht van de literatuur over rhabdomyolyse. De 
criteria voor de diagnose worden geformuleerd; de pathofysiologie van spier-
vezel necrose en de biochemische kenmerken van rhabdomyolyse worden 
besproken. De klinische kenmerken worden geïllustreerd aan de hand van een 
ziektegeschiedenis. Aandacht wordt besteed aan de complicaties van rhabdo-
myolyse die voor de clinicus van wezenlijk belang zijn. Alle tot dusver beken-
de verworven en erfelijke oorzaken van rhabdomyolyse worden weergegeven. 
Het hoofdstuk besluit met diagnostische richtlijnen en een leiddraad voor de 
behandeling van rhabdomyolyse. 
In het eerste deel van het proefschrift worden de ziektegeschiedenissen 
beschreven van 4 patiënten met ernstige en onverklaarde aanvallen van rhab-
domyolyse. Aanvullend onderzoek leidde tot nieuwe oorzakelijke factoren, 
die toegevoegd kunnen worden aan de lijst van reeds bekende verworven en 
erfelijke oorzaken van rhabdomyolyse. HOOFDSTUK 3.1 betreft een patiënt met 
een deficiëntie van midden-lange keten acylCoA dehydrogenase met een kli-
nisch debuut op volwassen leeftijd. In HOOFDSTUK 3.2 wordt een patiënt 
beschreven met rhabdomyolyse als gevolg van een dubbelinfectie met 
Epstein-Barr virus en echovirus 6. HOOFDSTUK 3.3 betreft een patiënt met een 
malaria tertiana infectie en een ernstige, gecompliceerde rhabdomyolyse, bij 
wie in tweede instantie een deficiëntie van myoadenylaat deaminase werd 
vastgesteld, HOOFDSTUK 3.4 beschrijft een patiënt met recidiverende aanvallen 
van rhabdomyolyse bij wie de ziekte van Brody, een deficiëntie van calcium 
adenosine trifosfatase, werd aangetoond. 
In het tweede gedeelte van dit proefschrift wordt nader ingegaan op de rol van 
de calcium homeostase in het proces van spiervezel necrose. Er wordt een ver-
gelijking gemaakt met het maligne hyperthermiesyndroom. Deze doorgaans 
door anesthetica uitgelokte aandoening, is de meest ernstige presentatie van 
rhabdomyolyse. Bij maligne hyperthermic is er sprake van een gestoorde in-
tracellulaire calcium regulatie en de therapie ter preventie en behandeling van 
deze potentieel letale aandoening bestaat uit de toediening van dantroleen. 
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Dantroleen is een spier relaxans dat de calcium afgifte vanuit het sarcoplasma-
tisch reticulum naar het cytosol remt. De diagnostische test voor maligne 
hyperthermic is de in vitro contractie test, waarbij een spierbiopt, blootge-
steld aan anaesthetica, wordt getest op hypercontractiliteit. 
HOOFDSTUK 4.1 beschrijft 6 patiënten met onverklaarde recidiverende 
rhabdomyolyse, die met deze in vitro contractie test werden onderzocht. Bij 5 
van hen was de test positief. Bij een van deze patiënten werd nader onderzoek 
verricht naar de intracellulaire calcium homeostase. Er bleek sprake van een 
gestoorde calcium regulatie, waarmee de veronderstelling van een causaal ver-
band tussen het optreden van rhabdomyolyse en een stoornis in de calcium 
homeostase werd bevestigd. Dit vormde aanleiding om ook bij niet door 
anesthetica geïnduceerde rhabdomyolyse de preventieve werking van dantro-
leen te onderzoeken. 
Daartoe werd allereerst een dierexperiment verricht, zoals beschreven in 
HOOFDSTUK 4.2. Bij mannelijke whistar ratten werd een rhabdomyolyse opge-
wekt met behulp van joodacetaat, een bekende stof die de glycolyse blokkeert. 
Een deel van de ratten werd voorbehandeld met dantroleen, een ander deel 
niet. Met naald electromyografie werden de ratten tot spieractiviteit geprik-
keld en de samengestelde spier actiepotentialen werden geregistreerd. De spie-
ren van de met dantroleen voorbehandelde ratten waren significant langer 
prikkelbaar en toonden minder stille electrische contracturen dan de niet met 
dantroleen voorbehandelde groep ratten. 
In HOOFDSTUK 4.3 wordt het onderzoek beschreven naar het effect van dan-
troleen bij vijf patiënten met de ziekte van McArdle. Deze glycogeensta-
pelingsziekte berust op een enzymdeficiëntie van de glycogenolyse en wordt 
o.a. gekenmerkt door recidiverende inspanningsgebonden rhabdomyolyse. 
Het risico op het ontwikkelen van rhabdomyolyse doet zich voornamelijk 
voor gedurende de eerst 10 à 15 minuten van lichamelijke inspanning. Vervol-
gens treedt het zogenaamde second wind fenomeen op, waardoor deze patiën-
ten na een kortdurende rust weer in staat zijn de inspanning te hervatten en 
voort te zetten. Er werd een dubbelblind, cross-over, placebo-gecontrolleerd 
onderzoek verricht naar het effect van dantroleen op de subjectieve spier-
klachten en de inspanningstolerantie tijdens fietsergometrische proeven met 
oppervlakte electromyografie. De resultaten toonden aan dat de patiënten 
aanvankelijk hinder ondervonden van de bijwerkingen van dantroleen in de 
zin van spierzwakte. In de loop van de behandelingsperiode verdwenen deze 
klachten. Bij de inspanningstesten werd er een positief effect van de medicatie 
vastgesteld op de energiecrisis voorafgaande aan het second wind fenomeen. 
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De in HOOFDSTUK 3.4 beschreven patiënt, lijdende aan een calcium adenosine 
trifosfatase dehydrogenase deficiëntie, ondervond een duidelijk positief effect 
van dantroleen, toegediend in lage dosering. De inspanningsgebonden aan-
vallen van rhabdomyolyse verdwenen en de spierklachten verbeterden. Bij tij-
delijk stoppen van de medicatie keerden de klachten en verschijnselen terug 
en verdwenen weer bij het hervatten van de medicatie. De ischemische 
inspanningstcsten toonden bovendien een abnormaal sterke stijging van het 
veneus bepaalde kalium als teken van spiervermoeidheid. Tijdens gebruik van 
dantroleen normaliseerden deze verhoogde kaliumspiegels. 
In HOOFDSTUK 4.4 wordt een patiënte beschreven met een stoornis van de 
mitochondriële oxidatieve fosforylering, die vanaf haar jeugd leed aan inspan-
ningsgebonden rhabdomyolyse aanvallen. Sinds het gebruik van dantroleen 
is zij aanvals- en klachtenvrij gebleven en heeft een toegenomen inspannings-
tolerantie verkregen. 
In HOOFDSTUK 5 worden de onderzoeksresultaten besproken en van kant-
tekeningen voorzien. Ten behoeve van de medicus practicus worden richtlij-
nen geformuleerd voor de diagnostiek en behandeling van rhabdomyolyse. 
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I 
Rhabdomyolyse is een syndroom met een kameleontisch aspect, dat 
zich onder verschillende, niet altijd eenvoudig te herkennen gedaanten 
kan presenteren, 
(dit proefschrift) 
2 
Een verhoging van de serum creatine kinase activiteit kan duiden op 
spierbeschadiging, maar is geen maat voor de ernst van de 
rhabdomyolyse. 
(dit proefschrift) 
3 
De medische behandeling bij ernstige rhabdomyolyse dient in het 
acute stadium vooral gericht te zijn op het voorkómen van de 
complicaties: acute nierinsufficiëntie, hartritmestoornissen en het 
compartimentsyndroom. 
(dit proefschrift) 
4 
Ter preventie van recidiverende inspanningsgebonden rhabdomyolyse 
is dantroleen in een lage aanvangsdosis een zinvolle proefbehandeling. 
(dit proefschrift) 
5 
Het veneus bepaalde kaliumgehalte tijdens de ischemische 
inspanningstest kan een bijdrage leveren aan de diagnostiek van 
neuromusculaire aandoeningen. 
(R.A. Wevers et al. J Inher Metab Dis 1992; 15:423-425.) 
6 
Bij geriatrische patiënten is het ontstaan van rhabdomyolyse bij acute 
ziekte en na een val meer gerelateerd aan de duur van de immobiliteit 
dientengevolge dan aan de primaire spierbeschadiging. 
(JAGS 1992;40:454-456) 
7 
De omschrijving van myoglobinurie (donker gekleurde urine) in de 
internationale literatuur als koffìekleurige, tea-coloured, cola-coloured 
of burgundy-like urine, zegt meer over de drinkgewoonte in de 
betreffende landen dan over het aspect van de urine. 
8 
De evidente verschillen én de opvallende overeenkomsten tussen de 
medische specialismen klinische geriatrie en pediatrie illustreren hoe 
zeer ook voor de levencyclus van de mens het franse gezegde opgeld 
doet dat "les extremes se touchent". 
9 
Een gestoorde conceptwisseling behoort tot de klinische verschijnselen 
van het frontaal syndroom. 
io 
Voor een goede communicatie in de patiëntenzorg is de simpele ver-
melding dat een patiënt lijdt aan een hemisyndroom tengevolge van 
een CVA in het a.cerebri media gebied, onvoldoende zonder expliciete 
aanduiding van het niveau van de ADL-functies. 
II 
De uitdrukking "iets in het achterhoofd houden" is niet in 
overeenstemming met de huidige inzichten in de topografie van het 
geheugen. 
12 
Een gezondheidsinstelling, die vooral vrouwelijke werknemers in de 
vruchtbare leeftijd aantrekt, dient ook structureel te voorzien in 
adequate regelingen voor vervanging bij zwangerschapsverlof. 
13 
Om bij wetenschappelijke publicaties onvindbaarheid in de literatuur-
lijst te vermijden, is het voor gehuwde vrouwen raadzamer de naam 
van hun vader (de "meisjes"naam) te gebruiken dan die van andere 
mannen. 
Nijmegen, 26 mei 1993. 


Λ V; · •• '•- i * у '•• >. "'••"•• 
Л •* •••
:
ί
 :
. »"
:
 î Г' 
ч 
STA т: 
н и 
ч 
/ X — 
* 
ч 
